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Schistosoma haematobium is the leading cause of urogenital schistosomiasis, which affects 
over 100 million people in tropical developing countries, and it is recognised as a class 1 
carcinogen due to the robust association of infection with bladder cancer. Proteins and other 
components, such as extracellular vesicles (EVs), present in the tegument and/or secreted by 
schistosomes enable the worms to survive in the host for years and studies documenting the 
proteomic composition of different helminths EVs have revealed many proteins involved in 
host-parasite interactions. Interestingly, crude EVs and EV membrane proteins, including 
tetraspanins (TSPs), of helminths can also be recognised by samples from infected animals, 
suggesting the potential usefulness of EVs for the development of novel diagnostic strategies. 
Moreover, EVs from helminths also contain vaccine candidate antigens, including TSPs, and 
immunisation of animals with EVs can reduce parasite burdens and pathogenesis in some 
models, demonstrating the vaccine potential of EV proteins. Herein, I have characterised the 
proteomic composition of S. haematobium adult worm EVs and assessed the vaccine and 
diagnostic potential of some of the characterised proteins. 
In chapter two, S. haematobium EVs, comprising both small EVs (sEVs) and medium/large 
EVs (m/lEVs), were purified from adult worms excretory/secretory products (ES). The size of 
each vesicle population was determined by qNano analysis; S. haematobium sEVs ranged from 
136 nm ± 12.4 to 191 nm ± 27.4 while the average size of m/lEVs was 249 nm ± 22.7. 
Following proteomic analysis, the most represented domains from sEVs were homologues of 
other helminths vaccine and drug targets, such as proteasome subunit, TSP family, ferritin-like 
and cytosol aminopeptidase domains. The most represented domains in S. haematobium 
m/lEVs were proteins involved in EVs biogenesis and release, including EF-hand, Ras family, 
TCP-1/cpn60 chaperonin family and TSP family domains. In addition, S. haematobium EVs 
	 V	
contained homologues of other helminth vaccine candidates, such as glutathione S-transferase 
(GST), TSPs, Saposin B domain-containing protein and calpain.  
In chapter three, six S. haematobium-TSPs (Sh-TSPs) (Sh-TSP-2, MS3_09198, MS3_01153, 
MS3_01370, MS3_05226 and MS3_05289) were selected from the proteomic analysis and 
further characterised. Based on their phylogenetic analysis, Sh-TSP-2, MS3_09198 and 
MS3_01370 grouped in the CD63 lineage of TSPs whereas MS3_05289, MS3_05226 and 
MS3_01153 clustered under the uroplakin family of TSPs. The expression levels of these 
Sh-TSPs were determined and all molecules were expressed throughout all life stages tested 
with different expression levels. The large extracellular loop (LEL) of each Sh-TSP was 
expressed in a bacterial expression system and polyclonal antibodies were raised to each 
molecule and used in localisation studies to determine the sites of anatomic expression. Sh-
TSP-2 and MS3_05289 were identified on the tegument of the worms, whereas MS3_01370, 
MS3_01153, MS3_09198 and MS3_05226 were identified both on the tegument and internal 
tissues of adult worms.  
In chapter four, the vaccine efficacy of three Sh-TSPs (Sh-TSP-2, MS3_09198 and 
MS3_01370) that clustered with known S. mansoni, S. japonicum and O. viverrini vaccine 
candidates was assessed using a homologous (hamster/S. haematobium challenge) model of 
infection. Furthermore, the cross-species protective efficacy of these Sh-TSPs was assessed in 
a heterologous (mouse/S. mansoni challenge) model of infection. Vaccination with Sh-TSPs 
did not significantly reduce adult worms burdens in the hamster model but significantly 
reduced the liver egg burden in both MS3_01370 and Sh-TSP-2 vaccinated groups (77.8% - 
P<0.01 and 52.27% - P<0.05, respectively). In two independent mouse trials, only the 
MS3_01370 vaccinated group (trial 1) displayed a significant reduction in adult worm burden 
(22% - P<0.05). Liver egg burden decreases were observed in groups vaccinated with Sh-TSP-
2 (trial 1, 32% - P<0.01; trial 2, 49% - P<0.001), MS3_01370 (trial 1, 39% - P<0.05; trial 2, 
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54% - P<0.001) and MS3_09198 (trial 1, 49% - P<0.001; trial 2, 27% - P<0.05). Similarly, 
intestinal egg burden decreases were observed in groups vaccinated with Sh-TSP-2 (trial 1, 
54% - P<0.001; trial 2, 27% - P<0.05), MS3_01370 (trial 1, 57% - P<0.01; trial 2, 36% - 
P<0.01) and MS3_09198 (trial 1, 51% - P<0.01; trial 2, 39% - P<0.05) 
In chapter five, the diagnostic efficacy of these Sh-TSPs was assessed by ELISA using serum 
from mice experimentally infected with S. haematobium and urine from infected individuals 
from an S. haematobium-endemic area of Zimbabwe. Sh-TSP-2, MS3_01370 and 
MS3_09198 were recognised by the serum of experimentally infected mice compared to serum 
from uninfected mice. To assess cross-reactivity with S. mansoni, an indirect ELISA was 
performed using the serum of mice experimentally infected with S. mansoni. Only 
MS3_09198, MS3_01370, MS3_05226 and MS3_01153 were recognised by antibodies from 
S. mansoni infected mice. The diagnostic efficacy of Sh-TSPs was further tested by their 
recognition of antibodies in urine from infected human subjects from an endemic area in 
Zimbabwe and all Sh-TSPs, each tested in isolation or combination, were recognised by 
infected individuals, including those with very low levels of infection (those positive for 
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Chapter 1: Introduction and literature review 
1. 1. Schistosoma haematobium and extracellular vesicles from helminths 
Schistosomiasis is a parasitic disease caused by blood dwelling trematodes from the genus 
Schistosoma. Six species of schistosomes can infect humans, including Schistosoma 
haematobium, Schistosoma japonicum, Schistosoma mansoni, Schistosoma mekongi, 
Schistosoma intercalatum and Schistosoma guineensis [1, 2]. The three most important species, 
in terms of morbidity and prevalence that can infect humans are S. haematobium, which causes 
urogenital schistosomiasis, and S. mansoni and S. japonicum, both causing intestinal 
schistosomiasis [2, 3]. While S. mansoni is prevalent in Africa, South America and the Middle 
East, S. japonicum occurs in Asia (primarily the Philippines and China) and S. haematobium 
infection is endemic in Africa and the Middle East (Fig 1.1). 
Schistosomiasis is the second most important parasitic disease, only after malaria, in terms of 
social, economic and public health impact [4]. Two hundred and fifty two million people are 
already infected, and 700 million people live in areas at risk [5]. Most of the schistosomiasis 
burden is found in Sub-Saharan Africa (SSA) [6], where around 280,000 people die annually 
due to the disease, particularly school-age children, adolescents and young adults [5], having 















Figure 1.1. Distribution of Schistosoma species. Adapted from [8]. 
Each schistosome species relies on a specific snail as intermediate host to complete its life cycle, 
and their dissemination is demarcated by their snail’s host territory [9]. The aquatic freshwater 
Biomphalaria and Bulinus snails are intermediate hosts for S. mansoni and S. haematobium, 
respectively, while Oncomelania species are the intermediate hosts for S. japonicum [8, 9]. The 
snails harbour different stages of the life cycle and liberate the infective stage (cercariae); while 
humans and other definitive hosts get infected when they come into contact with water 
containing cercariae during fishing, farming, swimming, washing and bathing [9]. 
Praziquantel is the only available drug for the treatment of schistosomiasis; however, it has a 
high cure rate by acting against the mature worms, but it is not effective against juvenile stages. 
A dose of 40 mg/kg is effective for the treatment of S. mansoni and S. haematobium infections, 
whereas 60 mg/kg is the recommended dose to treat S. japonicum and S. mekongi infection [10]. 
S. haematobium adult worms live in the perivesicular veins, whereas S. mansoni and S. 
japonicum adult worms live in the intestinal mesenteric veins [2, 11]. These worms can survive 
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in the host for years, using evasion strategies to remain undetected by the host immune system 
[12, 13], including the production of immunomodulatory proteins, which are present on their 
tegument and/or secreted by the worms. Due to the crucial role that proteins of the tegument 
and excretory/secretory (ES) products play in evading the host immune system, they have been 
the focus of different studies aimed at understanding host–parasite interactions and developing 
new therapeutic strategies [14-22]. The secretory products are substances that are secreted from 
parasite cells or glands and have defined biological roles whereas the excretory products are 
metabolic wastes that are released from the body [23]. Since schistosomes have a blind gut, the 
metabolic products are eliminated by regurgitation, therefore, the ES products consist of a 
mixture of secreted worm proteins and metabolic products occurring from physiological 
processes within the parasite [18].  
It has been recently shown that the ES products released by schistosomes, are not only a mixture 
of soluble proteins, lipids and glycans, but also contain extracellular vesicles (EVs) [24, 25], 
similarly to what happens in other parasites [26, 27]. EVs are membrane-bound structures of 
variable size (from 30 nm to 1,000 nm) that are released into the extracellular space by many 
different types of cells. They contribute to the transmission of bioactive molecules including 
proteins, lipids, DNA, and RNA between cells [28]. In mammals, they play a role in the 
maintenance of physiological processes and are also involved in the pathophysiology of 
diseases [29, 30]. Diverse parasites produce EVs, which can be internalised by host cells and 
can modulate the host immune response [26, 31]. These EVs are also involved in the pathology 
of parasitic disease and have great potential as new diagnostic tools and therapeutic agents 
against different parasitic pathogens [32]. 
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1.2. Schistosoma haematobium 
1.2.1. Epidemiology of Schistosoma haematobium infection  
S. haematobium, the causative agent of urogenital schistosomiasis, is highly prevalent in 53 
Middle East and African countries [2] and it is also sporadically seen in India [33] and France 
[34]. Urogenital schistosomiasis affects more than 90 million people, mostly in SSA, and 180 
million inhabitants live in endemic areas and are at risk [35]. Of these, around 70 million, 18 
million, 9.6 million and 32 million people suffer from schistosomal haematuria, bladder wall 
pathology, hydronephrosis, and dysuria, respectively; but, more importantly, urogenital 
schistosomiasis kills around 150,000 people per year [35]. 
1.2.2. Transmission and life cycle of Schistosoma haematobium  
Humans acquire urogenital schistosomiasis when they come into contact with water containing 
cercariae. Cercariae are shed by the snail host and once shed, cercariae survive for up to 1-3 
days [36]. They attach to and penetrate the human skin within 3–5 min [2], losing their tail and 
developing into schistosomula, which migrate through the bloodstream via the lungs to the 
liver and develops into mature worms in the portal vein. Finally, the adult worms migrate to 
the perivesicular veins and, after 4–7 weeks of infection, they start laying eggs [2]. The average 
survival time of the adult parasite in the host is 3–5 years, but they can survive for up to 30 
years [37]. Some of the eggs get excreted through urine while the rest of the produced eggs are 
carried away with the bloodstream and trapped in the tissues of different organs [8]. These 
trapped eggs in the tissues are the primary cause of pathology in humans. When the eggs are 
excreted into fresh water, they release the free-swimming miracidium stage, which locates a 
snail host using external stimuli such as snail-derived chemicals and sunlight. After they 
penetrate snails, miracidia develop into sporocysts, which undergo several rounds of asexual 












Figure 1.2. Life cycle of Schistosoma species. Adapted from.  
https://www.cdc.gov/parasites/schistosomiasis/biology.html 
1.2.3. Immunopathology of Schistosoma haematobium infection   
Cercariae enter into the human host and develop into schistosomula, which migrate through the 
bloodstream via the lungs to the liver and develop into mature worms in the portal vein [2]. 
During this time the host immune system is exposed to many antigens, however, in S. 
haematobium infections, the host immune response against cercariae, schistosomula and adult 
worm is limited compared to the response raised against the egg stage [38]. In non-human 
schistosomes, a hypersensitivity response against cercariae can cause swimmer’s itch [39] and 
in S. mansoni, the immune response against schistosomula can cause Katayama syndrome [40]. 
However, both symptoms are rare in S. haematobium infections, which is usually asymptomatic 
until egg production [41]. Cercariae activate the complement cascade when they enter the host. 
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Specifically, the membrane attack complex (C5–C9) acts against the cercariae, but they escape 
the immune response by rapidly discarding the glycoprotein cover (glycocalyx) from its 
membrane [42]. In S. mansoni, the schistosomulum covers itself with a new membrane, 
becoming resistant to the host’s immunological attack while developing into adult flukes [43]. 
Adult S. haematobium stimulates the host’s immune system eliciting an IgE antibody response, 
which is important against re-infection but cannot remove the parasite from the infected 
individuals [44]. Antibody response against S. haematobium infection is enhanced by drug 
treatment because S. haematobium worms killed by drugs such as praziquantel release antigens 
that motivate long-lived plasma cells to produce antibodies that can reduce S. haematobium 
fertility [45]. However, antibody production in S. haematobium infection is age-dependent and 
higher serum levels of IgM, IgG2 and IgG4 isotypes in children younger than 13 years block 
the protective effect of IgE [46]. 
Unlike the acute stage of the infection, eggs produced by adult S. haematobium stimulate a 
robust immune response within 24 h from local and recruited innate immune cells [47]. In an 
experimental animal model, at the early stage of egg production, the character of the initial 
immune response is mixed, with inflammatory mediators such as tumour necrosis factor (TNF-
α) as well as cytokines involved in T helper type 2 (Th2) responses [48]. Another mouse model 
of S. haematobium showed that cercariae infection combined with egg bladder wall injection 
stimulates local and systematic immune responses that are distinct from responses to egg 
injected bladder wall alone [49]. After 4-7 days of oviposition, eggs are engulfed by 
multinucleated macrophages, which are in turn surrounded by epithelioid macrophages and 
mixtures of eosinophils and neutrophils. Immune cells surrounding the eggs form a granuloma, 
which separates eggs from the surrounding tissue [48]. Then, a T helper type 1 (Th1) immune 
response ensues to eliminate the trapped egg, but the alteration of the immune response from 
Th1 to Th2 restricts this process [50]. In S. mansoni, IPSE/alpha-1 glycoprotein and omega-1 
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are responsible for the driving of a Th2 response [51-55]. The S. haematobium homolog of 
IPSE/alpha-1 glycoprotein has also been found in the mature eggs and it infiltrates HTB-9 
bladder cells and translocate to the nucleus [56] where it is thought to drive a Th2-biased 
immune response. IL-4 shifts the immune response by suppressing the differentiation of naive 
T cells to IFN-g producing cells and by stimulating differentiation of naïve T cells into IL-4-
producing cells [57]. IL-13 production stimulates activation of myofibroblast-like cells and 
accumulation of collagen, which ends up in tissue fibrosis [58]. Later on, IL-10 and regulatory 
T cells suppress the progression of chronic bladder fibrosis but in individuals with a 
polymorphism in the promoter gene for ficolin-2 the modulatory effect of IL-10 is suppressed 
[59], which may indicate that people with a polymorphism in the promoter gene for ficolin-2 
can suffer from bladder fibrosis during S. haematobium infection. 
The eggs trapped in capillary beds of urogenital organs stimulate the immune response. These 
immune responses against eggs trapped in the tissue lead to the formation of a granuloma that 
can lead to tissue fibrosis [48].Granulomas and sandy patches (small fibrotic nodules) cause 
inflammation (specially in the bladder) that lead to haematuria in some infected individuals 
[60]. The granuloma formed affects the bladder wall, leading to secondary urinary tract 
infection, renal infections, hydronephrosis, obstruction and general urinary dysfunction, which 
can progress to obstructive renal pathology [60, 61]. Furthermore, infected individuals can also 
develop squamous cell carcinoma [62].  
In female patients urogenital schistosomiasis can increase the risk of acquiring HIV infection 
[63]. Urogenital schistosomiasis has been suggested to be a risk factor for HIV infection for the 
following reasons: firstly, macroscopic tissue damage in female genital organs allows the virus 
to enter easily and facilitates the acquisition of HIV [64]; secondly, the inflammatory cells 
surrounding the eggs express CD4 T cell receptors, which are the target of HIV virus [65]; 
thirdly, the recruitment of immune cells to the male genital tract increases the viral load in 
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semen, which increases the risk of HIV transmission from male to female [66]; and, lastly, Th1 
cytotoxic responses are important in the initial control of HIV infection, and shifting of the 
immune response from Th1 to Th2 by schistosomiasis increases the risk of HIV infection [67]. 
1.2.4. Diagnosis of Schistosoma haematobium infection 
Microscopy examination of urine is the gold standard test for diagnosis of S. haematobium 
infection [68] and is necessary to determine the intensity of infection [41]. It is simple to 
perform and inexpensive [69] but cannot detect the acute stage of the disease (when no eggs are 
released) and consecutive examination of samples is required in light infections [11]. 
Detecting antibodies produced against the different developmental stages of S. haematobium is 
another diagnostic method for S. haematobium infections [70]. Antibody detection can help in 
the diagnosis of patients with a light egg load (or acute infection when microscopy examination 
is still negative) in low-level endemic areas [71], and can help determining re-emergence of 
schistosomiasis in certain areas and in the diagnosis of travellers [72]. However, one of the 
main limitations of this method is that it cannot differentiate between past and active infections 
[11, 41, 73]. 
The circulating cathodic antigen (CCA) rapid diagnostic test is an immunochromatographic 
dipstick that detects the presence of this schistosome glycan in patient urine [74]. For diagnosis 
of urogenital schistosomiasis, the sensitivity and specificity of this method is 88.2% and 96.4%, 
respectively [75]. However, the sensitivity of this technique is low in areas where S. mansoni 
and S. haematobium are co-endemic [76]. Similarly, a urine-based up-converting phosphor-
lateral flow circulating anodic antigen (UCP-LF CAA) assay is a highly sensitive and specific 
diagnostic method for S. haematobium infections in low endemic settings [77]. This technique 
is important to map distribution of schistosomiasis and assess drug efficacy [78]. In addition, 
the ability of the UCP-LF CAA test to detect a single pair of worms and its correlation with 
egg burden makes UCP-LF CAA the ideal measure of schistosomiasis infection [78]. However, 
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since it involves a centrifugation step, its applicability in field settings is limited [78]. 
Moreover, the CAA test is costly and not yet commercialised [77].  
Molecular techniques like PCR are highly specific and sensitive for S. haematobium diagnosis 
from patient serum, plasma or urine [79]. PCR is crucial to detect the parasite in the acute and 
chronic stage of the disease [80], essential to evaluate the efficacy of anti-schistosome drugs 
[81] and it is not affected by sample collection time, as is the case for urine samples [82]. 
However, DNA based diagnosis of helminths requires expensive equipment and reagents [83]. 
S. haematobium infection can also be diagnosed by taking cytology Papanicolaou (Pap) smears 
from infected female patients. This test method is simple to perform and cheap; however, its 
specificity is lower than real-time PCR for Schistosoma-specific DNA in vaginal lavage and 
urine samples, and urine microscopy [84]. 
1.2.5. Current status of Schistosoma haematobium vaccines 
The insufficient attention given to S. haematobium infection contributes to the widespread 
occurrence of the disease. Praziquantel treatment remains the cornerstone of control strategies; 
however, high reinfection rate requires frequent re-treatment and, in some infected people with 
high worm load, severe and irreversible pathology is usually diagnosed too late [85]. 
Furthermore, low efficacy of praziquantel has been reported from Egypt [86] and Senegal [87] 
and continuous use of praziquantel may lead to the development of resistance of S. 
haematobium to this drug. Hence, a vaccine is urgently needed for the control and elimination 
of urogenital schistosomiasis [85]. To alleviate this problem a number of trials have been 
undertaken to assess experimental vaccines. 
Irradiated cercariae and schistosomula have been tested as potential vaccine candidates [88]. 
Different groups of baboons were immunized repeatedly with 3 kRad- and 20 kRad-irradiated 
cercariae and schistosomula [88]. All vaccinated groups had reduced worm burden and faecal 
egg production rates (64-89% and 56-79%, respectively). The protective efficacy of cercariae 
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was higher than schistosomula, and 20 kRad-irradiated cercariae were more protective than 3 
kRad-irradiated cercariae [88]. Repeated immunisation of baboons with 20 kRad-irradiated 
schistosomula intramuscularly delayed and decreased faecal and urine egg production, reduced 
the size of granulomas, the gross pathology and the severity of inflammatory responses in the 
bladder and ureters; however, the proportion of tissue eggs in the liver of vaccinated animals 
didn’t decreased [89]. In another study 20- and 60- kRad-irradiated schistosomula protected 
baboons from S. haematobium infection by 85-90% and 56-50%, respectively [90]. The 
protective capacity of 20 kRad-irradiated schistosomula decreased over time [90].  
A schistosome glutathione S-transferase (Sh28GST) found in the schistosomula and adult 
stages of the parasite is the only vaccine candidate that has reached phase 3 trials against S. 
haematobium infection [91]. The vaccine efficacy of this antigen has been assessed in different 
Schistosoma species and this will be discussed later in this chapter.  
Calpain, a protein located on the tegument and underlying musculature of adult schistosomes 
[92], and its large subunit (Sm-p80) have been tested as recombinant vaccine candidates against 
S. mansoni infections in mice and non-human primates [93]. This S. mansoni vaccine also 
confers protection against S. haematobium infection [94] and this will be discussed later in this 
chapter.  
1.3. Extracellular vesicles 
EVs are membrane-bounded vesicles discharged from different cells. Based on their size and 
origin, three types of EVs can be differentiated: MVs, exosomes, and apoptotic bodies (Fig 
1.3) [95]. Exosomes are EVs produced from the endosomal system and they are formed as 
intraluminal vesicles (ILVs) in multivesicular bodies (MVBs) [96]. Initially, endocytic vesicles 
fuse with early endosomes; contents to be recycled are then organized into recycling 
endosomes, which transform into late endosomes. Then, ILVs accumulate on the late 
endosomes forming the larger MVBs. Finally, ILVs become exosomes and are released when 
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Figure 1.3. Types of extracellular vesicles. Adapted from [98]. 
MVs are EVs that are released from cell membranes of healthy cells. They are also called 
ectosomes, shedding vesicles or microparticles and their size ranges from 100-1,000 nm [99]. 
MVs are formed by direct external budding and fission of the cell membrane. The external 
budding is initiated by the dynamic interaction between phospholipid redistribution and 
cytoskeletal protein contraction [100]. The distribution of protein and phospholipid in the cell 
membrane is controlled by aminophospholipid translocase [100, 101] and this translocase 
transfers phospholipids from the inner leaflet to the outer leaflet, which induces membrane 
budding/vesicle formation. Finally, contraction of cytoskeletal structures by actin-myosin 
interactions completes vesicle formation [100]. External factors like calcium influx and 
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hypoxia promotes MV discharge [97]. Apoptotic bodies are released by dying cells and their 
size ranges from 50–5,000 nm [98]. During apoptosis cell and chromatin becomes shrieked 
and condensed, respectively. Then, extensive plasma membrane blebbing and nuclear 
fragmentation lead to the formation of apoptotic bodies [102].  
EVs play an important role in cell to cell communication [95]. EVs can also be involved in 
different pathological processes [103-105]. They are also involved in maintenance of 
homeostasis [106, 107] and can also serve as therapeutic agents [108]. 
1.3.1. Extracellular vesicles from helminths  
The characterisation of helminth proteomes is shedding light on the molecular basis of host–
pathogen interactions, with a view to discovering new diagnostic biomarkers and vaccine 
targets [109, 110], most of which are found at the external surface of the parasite and in the ES 
products [21, 111, 112]. Traditionally, the ES products were thought to comprise only soluble 
proteins, glycans, lipids, and nucleic acids [113]; however, recent literature has revealed that 
helminth ES products also contain EVs [26, 31]. Different parasites (including protozoans and 
helminths) have been shown to produce and secrete EVs which can be internalised by host cells 
and modulate the host immune response [26, 31]. These EVs are also involved in the pathology 
of parasitic disease and have great potential as new diagnostic tools and therapeutic agents 
against different parasitic pathogens [114, 115].  
The field of parasitic EVs attracted the attention of the scientific community very recently, 
when Marcilla et al. showed the first evidence of EV release from helminths in 2012 [116]. 
These EVs were identified from the tegument and ES products of the flukes Echinostoma 
caproni and Fasciola hepatica [116], and were shown to be internalised by intestinal cells, 
suggesting a role for EVs in host-parasite interaction and the development of infection [116]. 
Since then, EVs have been characterised in other parasitic helminths, including nematodes, 
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trematodes and cestodes, suggesting an important role for these vesicles in host-parasite 
interactions [24, 25, 117-126]. 
1.3.1.1 Nucleic acid and proteomic composition of helminth extracellular vesicles  
Since 2012, the number of “omic” resources to study helminth EVs has increased significantly, 
mainly due to the advancement of genomics and proteomics. The proteomes and genomes of 
several helminth EVs have been characterised [24, 25, 117-126], allowing for the identification 
of proteins and nucleic acids that could play an important role in host-parasite interactions. The 
nucleic acid composition of trematode EVs is complex, and different small RNAs and mRNAs 
have been characterised. Bernal et al. showed that EVs from Dicrocoelium dendriticum 
contains microRNAs (miRNAs) (eg: sma-let-7, sma-miR-2a-3p, emu-miR-71, emu-miR-190 
and sma-miR-61), demonstrating for the first time the presence of miRNAs in helminth EVs 
[124]. Similarly, molecular characterisation of S. mansoni schistosomula revealed 20 transfer 
RNAs (tRNAs) and 205 miRNAs [25], some of which (sma-bantam, sma-miR-10, sma-miR-
3479 and sma-miR-n1) have been detected in sera obtained from chronically infected hosts 
[127, 128] or within EVs from the sera of S. mansoni infected travelers (bantam and miR-2c-
3p) [129]. Similarly, Samoil et al. characterised the S. mansoni adult worm EVs and found 143 
miRNAs (eg: sma-miR-125b_R-1, sma-bantam, sma-miR-71a). Some of these miRNA were 
also detected in EVs isolated from mice serum suggesting a role of helminth EVs in host-
parasite interactions [130]. Likewise, EVs isolated from F. hepatica were shown to contain 
42 miRNAs, some of which were hypothesized to play a role in host manipulation [131]. In 
another study, EVs from S. japonicum adult worms were shown to contain a population of 
small RNAs associated with host gene regulation [119]. These EVs were internalised by 
murine liver cells in vitro and could downregulate the expression of the murine genes Gins4, 
Tysnd1 and Utp3 [119]. S. japonicum egg EVs have also been analysed, revealing different 
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types of RNAs such as rRNAs, small nuclear RNAs, repeat associated small RNAs, tRNAs 
and miRNAs [132].  
Similarly, the nucleic acid compositions of cestode EVs have been characterised [133]. The 
miRNA analysis of Taenia crassiceps EVs revealed 7 miRNAs (let-7-5p, miR-61-3p, miR-
190-5p, miR-219-5p, miR-4989-3p, miR-71-5p and miR-277-3p) whereas only one miRNA 
(let-7-5p) was detected in Mesocestoides corti EVs [133]. Based on an in silico miRNA target 
prediction approach, the most putatively regulated pathways in the mouse were those related 
to Wnt signalling, cadherin signalling, gonadotropin-releasing hormone receptor, inflammation 
mediated by chemokine and cytokine signalling and angiogenesis [133]. 
Like trematode parasite EVs, the nucleic acid composition of nematode EVs is also complex. 
For example, Heligmosomoides polygyrus EVs contain subpopulations of small RNAs 
miRNAs and yRNAs) that are involved in host gene regulation [125]; and Brugia malayi EVs 
contain miRNAs that down regulate the expression of host Let-7 [134], a gene involved in 
macrophage polarization and response to infection [135]. Trichuris muris EVs contain 475 full-
length mRNA transcripts involved in different roles such as signalling and signal transduction, 
transport, protein modification and biosynthetic processes, as well as in RNA processing and 
DNA integration [123]. Similarly, EVs from the same parasite also contained 56 miRNAs 
predicted to interact with genes involved in signalling, transcriptional regulation, metabolic 
and disease pathways and genes related with the host immune system [123]. In another study, 
the small RNA content of Nippostrongylus brasiliensis EVs were characterised and revealed 
52 miRNA (eg: miR-ev1, miR-ev2, miR-ev3, miR-ev4, miR-ev5) [122]. Based on a 
computational target prediction, these miRNAs were predicted to interact with genes involved 
with the immune system as well as in different processes such as signalling, metabolism and 
disease [122]. Analysing Ascaris suum EVs revealed 51, 40, 29, 39 and 42 miRNAs from L3 
larvae, L4 larvae, adult worm, adult worm body fluid and adult worm intestinal sections, 
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respectively [126]. These miRNAs were predicted to interact with genes involved in immunity 
such as IL-13, 1L-25 and IL-33 [126]. 
The proteomes of different trematode EVs have been characterised [24, 25, 117-119, 124, 125, 
134]. Proteomic analysis of E. caproni EVs revealed 51 different proteins including 
cytoskeletal proteins (actin, tubulin, myosin, paramyosin, tropomyosin), glycolytic enzymes 
(enolase, aldolase, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
Phosphoenolpyruvate carboxykinase (PEPCK), calcium-binding proteins (calmodulin, 
calponin), nuclear proteins (histones and elongation factors), stress-related proteins (eg: Heat 
Shock Proteins (HSPs)) and detoxifying enzymes (eg: peroxiredoxin). In addition to parasite 
proteins, vesicles from E. caproni adult worms also contained 36 host-derived proteins 
(including immunoglobulins, histones, partial sequences of mucins and metabolic enzymes) 
[116]. The presence of host proteins in the EV preparation is surprising and could be related to 
the method used for EV isolation, since only an ultracentrifugation was performed with no 
further gradient purification. In addition, the database used for matching peptides was not 
specific for the E. caproni genome (due to its unavailability), which could also affect the 
number and accuracy of identifications [116].  
Characterisation of the proteomes of S. mansoni adult worms and schistosomula EVs revealed 
83 and 109 proteins, respectively, including markers of exosomes such as TSPs, HSP, annexins 
and Rab11 as well as other proteins such as 14-3-3, cytoskeletal proteins and metabolic 
enzymes [24, 25]. Several proteins from S. mansoni adult worm EVs were homologous to 
proteins identified in the EVs from E. caproni (17, 20%), F. hepatica (24, 29%), D. 
dendriticum (17, 20%) and Opisthorchis viverrini (19, 23%), which allows researchers to 
speculate that there is a conserved mechanism for protein packaging inside trematode EVs. 
Interestingly, a total of 26 (31%) proteins found in S. mansoni adult worm EVs are homologues 
of previously described vaccine candidates [24] and they will be discussed later in this chapter. 
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The proteome of the S. mansoni adult worm EVs has been further characterised and 130 
proteins [130] were revealed. Of these 23 proteins including enolase, GAPDH, GST, 
calpain, leucine aminopeptidase, Sm20.8 and Sm22.6 were previously identified proteins 
from the adult worm EVs [24] and 25 of them such as taurocyamine kinase, enolase, GST, 
calpain, 14-3-3 epsilon and Sm20.8 were reported from schistosomula EVs [25]. Similarly, 
S. japonicum EVs contain 403 proteins from which 78 are homologous to exosomal proteins 
in other parasites. Proteomic analysis of the EVs secreted by the carcinogenic liver-fluke O. 
viverrini revealed 108 proteins including typical exosomal markers (TSPs, HSP-70), 
cytoskeletal proteins, regulatory proteins and trafficking proteins [117]. This study also showed 
the first evidence of exosome proteins in the tissues of an infected host (bile duct of infected 
hamsters and humans) [117]. EVs from F. hepatica were shown to be of a larger size range 
(30-200 nm in diameter) than other trematode EVs and contained some unique proteins, 
including helminth defense molecules (HDM), as well as known exosomal markers such as 
HSP-70, ALIX and TSPs [118]. In another study, the proteomic composition of the surface of 
adult F. hepatica EVs was characterised by using biotin to label the EVs surface [136] and 380 
proteins were identified including membrane transport proteins (pumps, channels and 
transporters), proteases (Cysteine peptidase, serine peptidase and metallo-peptidase), protease 
inhibitors (eg: Serpin7, serpin B6 and serpin B) and proteins involved in EVs biogenesis and 
release (ESCRT components, small GTPases, SNAREs and membrane structure and 
remodelling) [136]. Using a lectin microarray, the suface oligosaccharides were characterised 
and high mannose N-linked structures were present as well as N-or O-linked protein 
glycosylation and glycolipid structures [136]. Treatment of EVs with glycosidase blocked the 
internalisation of EVs by macrophages but treatment of EVs with serum from F. hepatica 
infected mice enhanced the internalisation of EVs by macrophages. Similarly, treatment of EVs 
with antibodies produced against surface proteins (CD63 receptor, DM9-containing protein 
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and myoferlin) enhanced the internalisation [136]. In another study, the proteomic composition 
of D. dendriticum revealed 84 proteins like metabolic enzymes (eg: catalase, GAPDH, enolase 
and aldolase), chaperons (HSP-70, annexins), metal-binding proteins (myoglobin-1 and 
MF6p/HDM-1), nuclear proteins (eg: histones, elongation factors and enzymes involved in 
RNA synthesis and processing) and signalling molecules (kinases, suppressor of 
tumorigenicity homologs and serpin homologs) [124].  
The proteomic composition of the different cestode parasites EVs has also been characterised. 
For instance, a proteomic analysis of Taenia crassiceps and M. corti EVs revealed 48 and 39 
proteins, respectively [133]. The most abundant proteins in the EVs secreted by Taenia 
crassiceps and M. corti were the immunodiagnostic proteins (H17g protein and a tegumental 
antigen) and proteins involved in EV transport such as receptor-mediated endocytosis family 
member and Ras GTPases [133]. In addition to these parasite proteins, host proteins such as 
immunoglobulins and complement factors were also found [133]. The proteomic content of 
EVs derived from Echinococcus granulosus hydatid cysts was characterised and 663 proteins 
were found [137]. Some of the most abundant proteins were antigen 5, alpha-mannosidase, 
malate dehydrogenase, gelsolin, lipid transport protein, antigen B subunit 4, expressed protein, 
syndecan binding protein syntenin, EG10 and antigen B 4/1 [137]. Among these proteins 
antigen 5, antigen B and EG10 are diagnostic antigens [138-140]. Proteins that are markers of 
EVs in mammalian systems like TSPs, transporters and channels (eg: ATPase and chloride 
channels and multidrug resistance associated protein) and proteins involved in EVs biogenesis 
and transport (eg: annexins, Rabs, ALIX and ubiquitin) were also identified [137]. Similarly, 
the proteome of EVs secreted by the protoscolex and the metacestode of E. granulosus were 
characterised by treating with loperamide. From the metacestode, 13 proteins were obtained 
including, gelsolin, HSP-70, TSPs and 14-3-3 protein, which are usually present in exosomes 
and 298 proteins were identified from the protoscolex including, exosomal markers (eg: 
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TSG101, TSPs, ALIX and annexin A6) [121]. The proteomic composition of EVs released by 
E. multilocularis metacestodes revealed 433 proteins including proteins involved in EVs 
biogenesis and release (eg: annexin, 14-3-3, tetraspanin, Rab and HSPs), cytoskeleton (actin 
and tubulin) and metabolism (eg: thioredoxin peroxidase, enolase and GAPDH) [120].  
In the case of parasitic nematodes, different proteomic studies have been performed [125, 134]. 
For example, EVs from H. polygyrus contained exosomal markers such as HSPs, TSPs, Rab 
proteins and ALIX [125], which are proteins involved in exosome biogenesis [97]. In another 
study, EVs from B. malayi were found to contain 32 proteins including markers of exosomes 
such as HSP-70, elongation factor-1α, elongation factor-2, actin, and Rab-1. Furthermore, more 
than 80% of these proteins were orthologous to mammalian exosome proteins [134]. The L3 
larvae and the adult male and female of B. malayi EVs were characterised and 31, 20 and 74 
proteins were identified [141]. Characterisation of Teladorsagia circumcincta EVs revealed 85 
proteins including proteins involved in EVs transport like Rab GTPases. EVs from this parasite 
were recognised by serum samples collected from T. circumcincta infected hosts, suggesting 
the usefulness of EVs for the diagnosis of helminth infection [142]. The proteome analysis of 
T. muris EVs revealed 364 proteins and the most abundant proteins were trypsin domain-
containing protein, sperm-coating protein (SCP)-like extracellular proteins, poly-cysteine and 
histidine-tailed protein and GAPDH. In addition, proteins typically found in EVs from 
helminths like 14–3–3, HSPs, GSTs and TSPs were found [24]. The proteomic analysis of N. 
brasiliensis EVs revealed a total of 81 proteins including proteins frequently present in 
exosomes like TSPs, enolase, 14-3-3 protein, HSPs and histones [122]. Characterising the 
protein composition of adult A. suum ES EVs revealed 268 proteins including, proteinases, 
peptidases, oxidases, reductases, kinases and HSPs [126]. Similarly analysing the proteomic 
composition of A. suum adult worm body fluid EVs revealed 125 proteins including HSPs, 
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peptidases, kinases and proteinases. Among these, 101 proteins were common to adult worm 
ES EVs [126]. 
In addition to exosome markers and vaccine candidates, it is worth noting the presence of other 
classes of proteins in the EVs of some helminths. For instance, saposin-like proteins have been 
detected in the EVs from S. mansoni and F. hepatica [24, 118]. These proteins are proposed to 
be haemolytic and play a role in the nutrient acquisition process of haematophagous parasites 
by disrupting red blood cell membranes to liberate haemoglobin [143]. EVs from different 
helminths also contain proteins that have been associated with immunomodulation, like 
annexins [24, 116, 117]. F. hepatica and B. malayi EVs contain cathepsin L [118, 134] that 
degrades host collagen to help parasite migration through host tissues [144] and peroxiredoxin, 
which shifts the host immune response from Th1 to Th2 by stimulation of M2 macrophages 
[118, 145]. The presence of these proteins in helminth EVs might indicate that the vesicles 
could be helping the parasite acquire nutrients, evade host immune responses and establish 
chronic infections and contribute to the associated pathogenesis.  
1.3.1.2. Vaccine candidates presented in helminth extracellular vesicles 
In addition to their role in pathogenesis and immunomodulation, EVs from helminths also 
contain vaccine candidate antigens (Table 1.1), which can be present in the cargo and 










Figure 1.4. Schematic representation of the most important vaccine candidates found in extracellular 
vesicles secreted by helminths [146]. 
1.3.1.2.1. Membrane proteins 
TSPs are membrane-spanning proteins that serve principally as membrane protein organizers 
[147]. The first members of this family were identified in humans [148] and in schistosomes 
[149]. Since then, this group of proteins has been found in both multicellular and unicellular 
organisms [150-152]. This family of proteins consists of four transmembrane domains, a small 
extracellular loop (SEL) and a LEL [147]. The LEL contains a conserved Cys-Cys-Gly motif 
(CCG motif), as well as other cysteine residues that facilitate the formation of disulfide bridges 
[153] and mediate specific protein-protein interactions with laterally associated proteins and 
a few known ligands [147]. The cytoplasmic regions provide links to cytoskeletal and 
signalling molecules. The four transmembrane domains stabilize individual TSPs during 













crucial for the assembly and maintenance of the tetraspan web [147]. In addition, 
juxtamembrane cysteine residues in the cytoplasmic domains provide sites for 
palmitoylation, contributing to the clustering of TSP microdomains. In general, the tetraspan 
web provides a scaffold by which membrane proteins are laterally organized to coordinate 
the intracellular transmission of external stimuli for the activation of signalling cascades 
[147].  
TSPs contribute to cellular physiology by organizing molecules within the plasma membrane 
into microdomains. Indeed, the proposed function of TSPs is to organise the plasma membrane 
by facilitating the formation of what are termed tetraspanin-enriched microdomains (TEMs) 
[154]. TEMs consist of homophilic and heterophilic interactions amongst TSPs, interactions 
between TSPs and other membrane proteins, as well as interactions between TSPs and proteins 
at the membrane/cytoplasm interface [154, 155]. Furthermore, TSPs are involved in many 
cellular activities such as differentiation, adhesion and division [156].  
In some helminths, TSPs play an important role in the formation of the tegument, the outermost 
membranous surface of the parasite that is in intimate contact with host tissues, and seem to be 
key molecules for the survival of the parasites [157-160]. TSP LELs have been shown to be 
efficacious vaccine antigens in a range of helminth infection models. Immunisation of mice 
with the LELs of two S. mansoni TSPs (Sm-TSP-1 and Sm-TSP-2) significantly decreased adult 
worm and liver egg burdens after infection with schistosomes [161] and Sm-TSP-2 has 
completed phase I clinical trials [162].  Similarly, vaccination of hamsters with the LEL of O. 
viverrini (Ov-TSP-2, Ov-TSP-3 and Ov-TSP-2 + Ov-TSP-3) significantly reduced adult worm 
burden and only Ov-TSP-2 reduced the fecal egg burden significantly [160]. In other studies, 
immunisation of mice with a fusion of the Sj23 TSP with other vaccine candidates significantly 
reduced the worm burden and liver eggs in a subsequent S. japonicum challenge [163-165]. 
Analysing the proteomes of different helminth EVs revealed several TSPs [24, 25, 117-123]. 
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Cwiklinski et al. provided the only in-depth characterisation of the proteins present in the 
membrane of F. hepatica-secreted EVs [118], confirming the presence of TSPs (as well as 
other proteins) in the membrane of F. hepatica EVs. Moreover, antibodies produced against a 
TSP present in O. viverrini EVs blocked the internalisation of EVs by cholangiocytes and 
decreased both cell proliferation and production of cytokines that stimulate tumorigenesis in 
this carcinogenic infection [117, 160]. These kind of studies characterizing the proteins present 
in the membrane of EVs and analysing their importance in cell contact and uptake will be key 
for the development of helminth EV-derived vaccines [136].  
Sm29 is a tegumental antigen, present in the tegument of adult worms and schistosomula of S. 
mansoni [166] and was recently found in S. mansoni adult worm EVs [24]. DNA immunisation 
of mice with this vaccine candidate resulted in 17-22% adult worm reduction [167], while 
immunisation with recombinant protein decreased adult worm, intestinal egg and liver egg 
burden by 51%, 60% and 50%, respectively [168]. Fusing Sm29 with S. mansoni fatty acid 
binding protein (FABP) decreased adult worm, liver egg and intestinal egg burdens by 40.3%, 
68.2% and 57.9%, respectively [169], whereas fusion with Sm-TSP-2 resulted in 24-35% adult 
worm reductions [167, 170]. In another study, mice were immunised with Sm29 formulated 
with alum or monophosphoryl lipid A adjuvants and Sm29 formulated with alum significantly 
protected mice by 29%-37% in two independent trials against S. mansoni reinfection. This 
protection was associated with high levels of antibodies against the Sm29 + alum formulation 
[171]. 
Calpain is a calcium-activated neutral cysteine protease [172] located on the tegument and 
underlying musculature of adult schistosomes [92], and has also been found in the EVs of 
different helminths [24, 25, 117, 120, 121]. Sm-p80 is the large subunit of calpain and has been 
tested as a vaccine candidate against S. mansoni infections [93]. In mice, administration of Sm-
p80 DNA vaccine, boosted with recombinant protein, reduced worm burden by 49%, whereas 
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immunisation with proteins provided 50% protection [173]. This vaccine candidate reduced 
worm and egg burden by 70% and 75%, respectively, using oligodeoxynucleotide as adjuvant 
[174]. The vaccine efficacy of Sm-p80 (rSm-p80) emulsified with glucopyranosyl lipid A + 
alum was assessed in mice in three independent trials. In trials one and two, vaccination of mice 
with rSm-p80 emulsified with glucopyranosyl lipid A + alum reduced adult worm burden 
significantly by 33.3% and 53.1%, respectively following S. mansoni challenge. In the third 
trial, worm reduction was not significant but intestinal egg burden was significantly reduced by 
75.5% [175]. The same vaccine candidates reduced adult worm burden by 38.5% in baboons 
but there was no significant reduction in the tissue egg burden [175]. Similarly, vaccination of 
baboons with rSm-p80 formulated with glucopyranosyl lipid adjuvant-stable emulsion (GLA-
SE) significantly reduced liver egg burden and egg-hatching rate of S. mansoni by 67.7% and 
85.6%, respectively, which indicates the potential usefulness of this vaccine candidate in 
blocking disease transmission [176]. Moreover, this S. mansoni vaccine confers partial 
protection against S. haematobium and S. japonicum infection [94, 177]. Vaccination of mice 
with rSm-p80 emulsified with GLA-SE intramuscularly resulted in 46.75% reduction in adult 
worm burden but no significant reduction in tissue egg burden following S. japonicum challenge 
was observed [177]. Administration of recombinant Sm-p80 emulsified with GLA-SE in 
hamsters reduced S. haematobium adult worm and tissue egg burden by 48% and 64%, 
respectively [94]. Similarly, in baboons, the Sm-p80/GLA-SE vaccine produced a 25%, 64% 
and 53% reduction in adult worms, urinary bladder egg load and in urine egg output, 
respectively following S. haematobium challenge [94].  
Paramyosin is a protein present in the thick muscle myofilaments of invertebrates [178]. This 
protein is located on the granules of the post-acetabular glands of cercariae, within the tegument 
matrix and surface of schistosomula of S. japonicum [179] and on the teguments of adult S. 
mansoni [180]. Paramyosin is considered a promising vaccine candidate against S. japonicum 
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[181]. Immunisation of pigs with recombinant paramyosin resulted in 33-34% reduction in S. 
japonicum adult worm burden [181], whereas immunisation of mice with parasite-derived 
paramyosin resulted in 62%-86% reduction in adult worm burden following S. japonicum 
infection [182]. The vaccine efficacy of paramyosin emulsified with ISA206 adjuvant was 
assessed in three independent trials in water buffalos [183]. In the first trial, immunisation of 
water buffalos with recombinant paramyosin protein reduced worm burden by 51.5 % but the 
reduction was not statistically significant [183]. Increasing the dose in the second and third 
trial significantly reduced the adult worm burden by 57.8% and 57.8%, respectively [183]. 
Interestingly, this protein has been found in the EVs of O. viverrini [117]. 
1.3.1.2.2. Proteases and peptidases 
Leucine aminopeptidases are metallopeptidases that cleave N-terminal residues from proteins 
and peptides [184], and their vaccine efficacy against F. hepatica has been evaluated in animal 
models [185, 186]. Immunisation of sheep with native and recombinant leucine aminopeptidase 
resulted in 49-89% adult worm reduction in subsequent F. hepatica challenges [185, 186]. 
Furthermore, leucine aminopeptidase was shown to be abundant in the EVs from S. mansoni 
and F. hepatica [24, 118].  
Cathepsin L is a protease that has been found in the EVs of F. hepatica and B. malayi [118, 
134]. Immunisation of cattle and sheep with parasite-derived cathepsin L resulted in 42-69% 
and 34% reduction in F. hepatica adult worm burdens, respectively [186, 187], while in another 
study, immunisation of cattle with recombinant cathepsin L resulted in a 48% reduction in adult 
worm burden [188]. Immunisation of mice with recombinant cathepsin B resulted in 59%, 56% 
and 54% reductions in adult worm, liver egg and intestinal egg burdens, respectively, following 
S. mansoni challenge [189]. Furthermore, cathepsin B has also been found in F. hepatica and 
S. japonicum EVs [118, 119, 142]. 
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1.3.1.2.3. Cytosolic proteins 
Saposins are activators of sphingolipid hydrolases [190] that have been used in vaccine trials 
against different helminths [143, 191]. For instance, immunisation of rabbits with a 
recombinant saposin-like protein reduced adult worm burden and faecal and bile egg loads by 
81.2%, 83.8% and 73%, respectively, after F. hepatica challenge [191]. Similarly, vaccination 
of mice with recombinant saposin-like protein 1 (rFgSAP-1) from Fasciola gigantica 
emulsified with aluminium hydroxide gel (alum) stimulated the production of antibody 
responses that resulted in 73.2% and 74.3% protection when compared with non-vaccinated 
infected and adjuvant-vaccinated infected controls, respectively. Importantly, this vaccine 
candidate reduced levels of liver damage [192]. Saposin domain-containing proteins have been 
revealed in the EVs of several helminths, including S. mansoni, F. hepatica, N. brasiliensis and 
T. circumcincta [24, 118, 122, 142]. 
GSTs are group of enzymes that detoxify endogenous compounds and foreign chemicals [193]. 
This protein has been tested as a vaccine candidate against different helminth infections [194-
196] and has recently been found in the EVs of different helminths [24, 117-119, 121]. 
Immunisation of mice and baboons with Sm28GST as a recombinant protein affects both worm 
viability and fecundity [197] and the antibody produced against this enzyme blocks its activity, 
leading to a reduction in female worm fecundity and egg viability [194]. The S. haematobium 
homologue, Sh28GST, is a promising vaccine candidate against S. haematobium infections. In 
the animal model, the antibody produced against this vaccine candidate can deactivate 
Sh28GST action and downgrade egg-production, which decreased urinary tract pathology and 
the spread of the disease [198]. Clinical trials using Sh28GST indicated that this vaccine has a 
good safety profile and stimulates the production of IgG3 [199]. In naturally infected 
individuals, the cellular immune response against Sh28GST is boosted by praziquantel 
treatment, increases in younger age groups and increases with schistosome infection status 
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[200]. A Phase 3 trial was conducted from 2009 to 2012 in S. haematobium infected children 
to assess the efficacy of the vaccine candidate after treatment with praziquantel, but the 
protective efficacy was not significant [91]. In another study, administration of the S. japonicum 
homologue as a DNA vaccine (Sj26GST) with IL-18 significantly decreased worm burdens, 
liver and faecal eggs counts in a subsequent S. japonicum challenge in mice [195]. Furthermore, 
F. hepatica GST has been evaluated in different animal models with the mean protective 
capacity reported as 29% and 43% in sheep and cattle, respectively [196, 201]. 
FABP is a cytosolic protein that aids the parasite with absorption, transportation and sorting of 
host fatty acids [202]. This molecule has long been considered a potential vaccine candidate in 
different helminths [203-205] and it has recently been found in S. mansoni and F. hepatica 
adult worm EVs [24, 118, 133]. Immunisation of cattle with parasite-derived FABP from F. 
hepatica (FhFABP) resulted in a 55% adult worm reduction [203], while immunisation of 
sheep decreased adult worm, intestinal egg and bile fluid egg burdens by 24%, 40.3% and 
51.8%, respectively [206]. Immunisation of sheep with recombinant FhFABP resulted in a 43% 
adult worm reduction [207]. Similarly, immunisation of mice, rats and sheep by fusing SjFABP 
with GST decreased S. japonicum adult worm burdens by 34.3%, 31.9% and 59.2%, 
respectively [204], whereas administration of SjFABP DNA vaccine + IL-18 resulted in 38% 
and 45% S. japonicum adult worm and egg burden reduction [208]. Immunisation of mice with 
recombinant SmFABP resulted in a 67% S. mansoni adult worm reduction [205]. 
1.3.1.2.4. Extracellular vesicles as vaccines against helminths  
Since helminth EVs contain a significant number of vaccine candidates, using these EVs to 
immunize the host might be a good strategy for the development of vaccines against helminth 
infections. For instance, EVs from H. polygyrus stimulated the production of antibodies that 
significantly reduced faecal egg counts and intestinal worm burdens after subsequent H. 
polygyrus challenges [209]. In another study, immunisation of mice with EVs from E. caproni 
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produced both humoral and cellular immune responses, which reduced symptom severity and 
mortality induced by infection [210]. T. muris- and O. viverrini-derived EVs have also been 
shown to induce immunity and confer protection against subsequent infection [160, 211].  
While protective immunity has been shown with numerous helminth EVs in animal models, 
the specific proteins responsible for the induction of protective antibodies have not been 
characterized. Moreover, the immune response against EVs might differ between helminths, 
so further work is required to characterize the immunogenic proteins present in helminth EVs.  
These findings suggest that helminth EVs are important in host–parasite interactions, and they 
can also be used in the discovery of new vaccine candidates. Since the isolation and purification 
of EVs is time consuming and might not be feasible at a larger scale, the characterisation of 
the proteomic composition of EVs will be key for the development of new vaccines. In addition 
to well-characterised molecules, there is a large number of hypothetical proteins in helminth 
EVs, which, arguably play parasitism-specific roles and might be good vaccine targets [212]. 
For this purpose, a better annotation of genomes using different approaches such as in silico 
analyses and proteogenomic studies will be of invaluable help [110]. 
1.3.1.3. Role of helminth extracellular vesicles in immunomodulation   
EVs secreted by different helminths can modulate the host’s immune response. For instance, 
EVs secreted by the murine intestinal nematode H. polygyrus contain miRNAs and yRNAs, 
which suppress the host immune response [125]. Intranasal administration of H. polygyrus EVs 
together with the extracts of the allergenic fungus Alternaria decreased bronchoalveolar 
eosinophilia, suppressed the expression of the Th2 cytokines IL-5 and IL-13 by innate lymphoid 
cells and also decreased the expression of the IL-33 receptor in mice [125]. Internalisation of 
EVs by mouse cells transferred miRNAs which resulted in suppressed expression of Dusp1 and 
Il1rl1 [125]. Dusp1 is a key regulator of mitogen-activated protein kinase signalling and 
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inhibits type 1 pro-inflammatory reactions. IL1rl1 is, the ligand-specific subunit of the receptor 
for IL-33, a key alarmin cytokine required for protection against multicellular parasites, which 
is produced by innate cells to drive early Th2 immune responsiveness [213]. The above finding 
correlates with previous studies using ES products [214]. Intranasal co-administration of the 
ES products of the same parasite with Alternaria extracts suppressed IL-33 release, production 
of IL-4, IL-5, and IL-13, and localized eosinophilia [214]. Thus, this parasite targets IL-33 
production as part of its suite of suppressive effects, and thereby preventing the development 
of the Th2 immune response to infection and allergic sensitization [214]. Furthermore, EVs 
from the same parasite were internalised by macrophages and supressed their activation [209]. 
These studies showed that the ES products from H. polygyrus contains exosomes that facilitate 
the parasite’s ability to escape the host’s immune response. Similarly, EVs from N. brasiliensis 
prevent colitis induced by trinitrobenzene sulfonic acid (TNBS) in a mouse model of 
inflammatory bowel disease by suppressing pro‐inflammatory cytokines (IL‐6, IL‐1β, IFN‐γ 
and IL‐17a) and inducing the expression of the anti‐inflammatory cytokine IL‐10 [122]. 
The third stage larvae of B. malayi secrete EVs, which can be internalised by J774A.1 cells 
(murine macrophages), activating them and significantly increasing the production of G-CSF, 
MCP-1, IL-6 and MIP-2 levels. This indicated that the EVs produced by B. malayi generate a 
classical pro-inflammatory macrophage phenotype [134]. EVs from S. japonicum contain 
miRNAs and potential virulence factors [119]. Internalisation of these EVs transferred 
miRNAs to mice that downregulate expression of the Gins4, Tysnd1, and Utp3 genes [119]. 
The EVs released from S. japonicum modulate cytokine production in RAW264.7 cells. 
Treatment of RAW264.7 cells with EVs increased iNOS expression, TNF-a secretion and 
CD16/32 expression in vitro. In contrast, the expression of CD206, Arg-1, and IL-10 by 
RAW264.7 cells was decreased in cells treated with EVs. The increase in the surface 
expression of CD16/32, iNOS expression, TNF-a secretion and the decrease in the expression 
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of CD206, Arg-1, and IL-10 indicated that S. japonicum EVs modulate the phenotype of 
macrophages and skew macrophages to M1 polarization [215]. E. granulosus EVs can be 
internalised by murine dendritic cells and affecting expression of activation markers such as 
CD86 and MHCII, indicating that E. granulosus EVs could interfere with the antigen 
presentation pathway [121]. Similarly, EVs released by E. multilocularis metacestodes 
decreased nitric oxide (NO) secretion by down regulating inducible nitric oxide synthase 
(iNOS) in RAW264.7 macrophages [120]. These studies show that EVs from helminths can 
modulate the host’s immune response to escape the host mediated immune attack. 
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Table 1.1. Efficacy of different vaccine candidates present in the extracellular vesicles (EVs) from helminths. Table summarizing the most important proteins 
found in EVs from helminths that have been tested as vaccine candidates against helminth infections. Ns: not significant; RP: recombinant protein; GST: 
glutathione S-transferase; As: Ascaris suum; Bm: Brugia malayi; Dd: Dicrocoelium dendriticum; Ec: Echinostoma caproni; Eg: Echinococcus granuloses; 
Em: Echinococcus multilocularis; Fh: Fasciola hepatica; Hc: Haemonchus contortus; Hw: hook worm; Ov: Opisthorchis viverrini; Sh: Schistosoma 
haematobium; Sj: Schistosoma japonicum; Sm: Schistosoma mansoni; Tm: Trichuris muris 




Helminth in which 
vaccine trial was done 
Adult worm 
reduction 
Egg reduction Antigen present 




Mouse Sm 57% 64% Sm, Ov, Fh, Sj, 






Mouse Sm 34% 52% 
RP (Ov-
TSP-2) 
Hamster Ov 34% 41% [160] 
RP (Ov-
TSP-3) 
Hamster Ov 30% Ns 
Calpain DNA Mouse Sm 70% 75% Sm, Ov, Sj and Eg 
 
[174] 
RP Hamster Sh 48% 64% [94] 
Saposin containing 
protein 
RP Rabbit Fh 81.2% 83.8% (fecal) and 73% 
(bile) 
Sm and Fh [191] 
RP Mouse Sm Ns - [143] 
Sm29 
 
DND Mouse Sm 17-22% - Sm [167] 


















Mouse Sm 35% - 
22.6 kDa tegument 
antigen 
RP Mouse Sm 34.5% - Sm and Sj [216] 
Thioredoxin peroxidase RP Mouse Sj 37.02% 56.52% Sm [217] 
Syntenin RP Mouse Sm 30-37% - Sm, Ov and Fh [218] 
Dynein light chain (DLC 
12 and DLC 13) 
RP Mouse Sm 43% and 51% - Sm and Sj [219] 
Antigen Sm21.7 DNA Mouse Sm 56% 41.53% (liver) and 











































































Leucine amino peptidase 
(M17 family) 
RP Sheep Fh 49-86% - Sm and Fh [185] 
Native 
protein 
Sheep Fh 89% - [186] 
14-3-3 protein RP  Sm 25-46% - Sm, Ov, Ec and 
Fh 
[222] 




Cattle Fh 55% - Fh and Sm [203] 
Sheep Fh 24% 40.3% (fecal) and 58.1% 
(bilefluide) 
[206] 
RP Sheep Fh 43% - [207] 
RP +GST Mouse Sj 34.3%, - [204] 
Rats Sj 31.9%, - [204] 




Mouse Sj 38% 45% [208] 
RP Mouse Sm 67% - [205] 
Cathepsin L Native Cattle Fh 42-69% - Fh and Bm [187] 
Sheep Fh 34% - [186] 
RP Cattle Fh 48% - [188] 
Goat Fh Ns  [223] 
Cathepsin B RP Mouse Sm 59% 56% (liver) 54% 
(intestinal) 
Fh and Sj [189] 
Kunitz type molecule Native Sheep Fh Ns - Fh [201] 











RP Pig Sj 33-34% - Ov [181] 
Native Mouse Sj 62%-86%, - [182] 
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Introduction to the study 
There is no licenced and effective vaccine to control the transmission of S. haematobium 
infection. Similarly, there are also limitations within the current diagnostic modalities of S. 
haematobium infection. However, EVs from helminths contain vaccine candidate antigens and 
vaccination of animals with helminths EVs stimulates production of antibodies that 
significantly reduce egg counts and worm burdens. Furthermore, EVs from helminths also 
contain diagnostic marks of infection and can also be recognised by antibodies produced from 
infected animals. These observations demonstrated the usefulness of EVs in vaccine and 
diagnostic strategies. Hence, the main aim of my thesis will be characterising the proteomic 
composition of S. haematobium adult worm EVs and testing selected antigens as vaccine and 
diagnostic candidates. 
Aims of this thesis: 
1. Characterisation of the proteomic composition of S. haematobium adult worm EVs 
2. Characterisation of TSPs from S. haematobium EVs 
3.  Assessment of the vaccine efficacy of S. haematobium TSPs 




Chapter 2: Characterisation of the proteomic composition of 
Schistosoma haematobium adult worm extracellular vesicles 
2.1. Introduction 
Adult Schistosoma worms survive in the host for years and proteins on the worm tegument and 
in ES products are vital to this immune evasion strategy. ES products are molecules released 
by worms and comprise different proteins, glycans, lipids, and nucleic acids [113]. They play 
a crucial role in evading the host immune system and have been the focus of different studies 
aiming at understanding host-parasite interactions and the development of novel therapeutics 
[18-20, 22]. Because of a blind gut, schistosomes metabolic products are removed by vomiting; 
therefore, schistosome ES products consist of a mixture of secreted worm molecules and 
metabolites [18]. 
Recently, it has been documented that the ES products from different helminths (including 
schistosomes) contain EVs [26, 115, 146]. EVs are membrane-bound organelles released by 
cells that can act as mediators of intercellular communication by transferring molecular signals 
mediated by proteins, lipids, metabolites, mRNAs, microRNAs and other non-coding RNA 
species [226, 227]. In addition to the transmission of information, EVs are also involved in the 
maintenance of normal physiology [228, 229] and in the pathological process [230].  
The first evidence of EV release from helminths was reported from the tegument and ES 
products of E. caproni and F. hepatica [116]. Since then, EVs have been characterised in many 
other helminths, including nematodes, trematodes and cestodes [24, 25, 117-126]. Studies have 
shown that EVs from helminths are heavily involved in host-parasite interactions [24, 25, 117-
126]. For instance, EVs from trematodes and nematodes can be internalised by host cells, 
modulate host immune responses [125, 134, 215] and are involved in pathogenesis [117]. In 
addition, EVs also have enormous potential as novel diagnostic tools to detect parasitic 
infections [142] as proteins on the surface of helminths EVs have been found to be potential 
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diagnostic candidates [159, 231]. Furthermore, EVs from helminths also contain vaccine 
candidate antigens. For example, EVs from S. mansoni contain molecules that have shown 
vaccine efficacy in animal models of schistosomiasis [24]. Vaccination of mice with helminth 
EVs stimulates the production of protective immune responses that significantly reduce faecal 
egg counts; worm burdens, symptom severity and mortality induced by infection in subsequent 
parasite challenges [31, 160, 210, 211]. Moreover, antibodies produced against recombinant 
forms of O. viverrini EV surface proteins hinders the uptake of EVs by cholangiocytes and 
suppresses the immune response that fuels pathogenesis [117, 160].  
In addition to their roles in pathogenesis and diagnostic and vaccine potential, EVs from 
helminths are also useful in immunotherapeutic applications [122, 125, 232]. For example, 
administration of EVs from H. polygyrus suppresses type 2 innate responses and lung allergen‐
induced eosinophilia and asthma in mice [125]. Similarly, EVs from N. brasiliensis prevents 
colitis induced by trinitrobenzene sulfonic acid (TNBS) in a mouse model of inflammatory 
bowel disease [122]. Furthermore, administration of F. hepatica EVs to mice decreases the 
expression of pro‐inflammatory cytokines, reducing disease severity in dextran sulfate sodium 
(DSS)‐induced colitis [232].  
These observations demonstrate the importance of EVs in helminth-host interactions and their 
usefulness in vaccine, diagnostic and therapeutic applications. This chapter aims to characterise 
the proteome composition of different EV populations obtained from S. haematobium adult ES 
products. Using a proteomic approach, combined with newly available S. haematobium 
genome and transcriptome resources, I have defined the protein composition of S. 
haematobium adult worm EVs.  
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2.2. Materials and methods 
2.2.1. Parasite materials and experimental animals 
Bulinus truncatus snails infected with S. haematobium (Egyptian strain) were provided by the 
Biomedical Research Institute, MD, USA. Snails were maintained in aquaria in a 27°C 
incubator. 
Male BALB/c mice were purchased from the Animal Resource Centre, Canningvale, 
Western Australia and maintained at the AITHM animal facility in cages under controlled 
temperature and light with free access to pelleted food and water. All experimental procedures 
performed on animals in this study were approved by the James Cook University (JCU) 
animal ethics committee (A2391). All experiments were performed in accordance with the 
2007 Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
and the 2001 Queensland Animal Care and Protection Act. 
2.2.2. Cercariae shedding and mice challenge 
Snails were removed from the tank with a pair of forceps and washed several times with water 
to remove debris and rotifers, transferred to a Petri dish and incubated without water at 27°C 
in the dark for 2 h. Water was added and the snails were placed under light for 1.5 h at 28°C. 
Cercariae were concentrated using a 20 µm pore size sieve and finally, each BALB/c mouse (6 
week-old) was infected with 1,000 cercariae by tail penetration [233]. 
2.2.3. Adult worm culture and ES collection 
S. haematobium adult worms were obtained by perfusion of mice at 16 weeks post-infection 
and parasites were washed several times with serum-free modified Basch media supplemented 
with 4´ antibiotic/antimycotic (SFB) and then incubated in SFB (50 pairs/5 ml) at 37°C in with 
5% CO2 [24]. Dead worms were removed and media containing ES products was harvested 
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every 24 h for 2 weeks. Every day, ES products were differentially centrifuged at 4°C (500 ´g, 
2,000 ´g and 4,000 ´g for 30 min each) to remove large parasite material such as eggs and 
tegumental debris and stored at -80°C. 
2.2.4. Purification of extracellular vesicles  
Stored supernatants were thawed on ice, concentrated at 4°C using a 10 kDa spin concentrator 
(Merck Millipore, USA) and centrifuged for 1 h at 15,000 ´g at 4°C. The resultant pellet 
(containing m/lEVs) was washed with 1 ml of PBS, centrifuged at 15,000 ´g for 1 h at 4°C, 
resuspended in 200 μl PBS and stored at -80°C. The supernatant was ultracentrifuged at 
120,000 ´g for 3 h at 4°C using an MLS-50 rotor (Beckman Coulter, USA) to collect sEVs. 
The resultant pellet was resuspended in 70 μl of PBS and subjected to Optiprep® density 
gradient (ODG) separation. The ODG was prepared by diluting a 60% Iodixanol solution 
(Optiprep®, Sigma-Aldrich, USA) with 0.25 M sucrose in 10 mM Tris-HCl pH 7.2 to make 
40%, 20%, 10% and 5% iodixanol solutions, and 1.0 ml of these solutions was layered in 
decreasing density in an ultracentrifuge tube. The resuspended sEVs were added to the top 
layer and ultracentrifuged at 120,000 ´g for 18 h at 4°C. A control tube was similarly prepared 
using PBS instead of sEVs to measure the density of the different sEV fractions recovered from 
the gradient. sEV fractions obtained from the ODG were diluted with 8 ml of PBS containing 
1 × EDTA-free protease inhibitor cocktail (Santa Cruz, USA), and concentrated using a 10 kDa 
spin concentrator to remove the excess of Optiprep® solution. All sEV fractions were kept at 
-80°C until use. 
The density of different sEV fractions obtained from the ODG was determined as follows. A 
total of 12 fractions each were collected from the sample and control tube. Then, 100 μl from 
each fraction obtained from the control tube was diluted (1:1) with water (twice). The 
absorbance of each fraction was measured at 340 nm using a POLARstar Omega (BMG 
	 38	
Labtech, Australia) and the density of each sEV fraction was determined by interpolating the 
absorbance in a standard curve as previously shown [24]. The protein concentration of 
sEVfractions and m/lEVs was quantified using the Quick Start™ Bradford Protein Assay Kit 
(Bio-Rad Laboratories, Inc. Life Science Research, USA) following the manufacturer’s 
instructions.   
2.2.5. Determination of the size and concentration of extracellular vesicles 
The size distribution and particle concentration of the different sEV fractions recovered after 
ODG and m/lEVs was measured using tunable resistant pulse sensing (TRPS) using a qNano 
instrument (Izon, New Zealand) following an established protocol [122]. A Nanopore NP150 
and NP400 (Izon, New Zealand) was used to measure sEVs and m/lEVs, respectively. Thirty-
five μl of measurement electrolyte (Izon, New Zealand) was added to the upper fluid well and 
maximum pressure was applied; the shielding lid was clicked 5 to 10 times to wet the 
Nanopore. Then, 75 µl of measurement electrolyte was added to the lower fluid well, maximum 
pressure and an appropriate voltage (0.1 V) was applied and Nanopore current was checked for 
stability. Thirty-five and 75 μl of filtered coating solution (Izon, New Zealand) was loaded in 
the upper and lower fluid well, respectively, and maximum pressure was applied for 10 min 
followed by maximum vacuum for another 10 min. The coating solution was flushed out of the 
upper and lower fluid wells two to three times with measurement electrolyte, maximum 
pressure was applied for 10 min and the voltage was increased until the current reached 
between 120 and 140 nA and the baseline current was stable. Then, 35 μl of calibration particles 
(CP200 carboxylated polystyrene calibration particles) (Izon, New Zealand) was loaded to the 
upper fluid well at a 1:200 dilution for sEVs and 1: 1,500 for m/lEVs, incubated for 2 min at 
maximum pressure and the stretch was reduced and the calibration particles were measured at 
2 different pressures (P10 and P5). The S. haematobium sEV fractions and m/lEVs were diluted 
1:5-1:10 and applied to the Nanopore and measured similarly to the calibration particles. The 
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size and concentration of particles were determined using the software provided by Izon 
(version 3.2).  
2.2.6. Proteomic analysis of extracellular vesicles 
2.2.6.1. In- gel trypsin digestion 
All S. haematobium sEV fractions and m/lEVs were resuspended in 1x loading buffer (10% 
glycerol, 80 mM Tris-HCl, 2% SDS, 0.01% bromophenol blue and 1.25% beta-
mercaptoethanol, pH 6.8), boiled at 95°C for 5 min and electrophoresed in a 15% SDS-PAGE 
at 100 V. The gel was stained with 0.03% Coomassie Brilliant Blue (40% methanol, 
10% acetic acid and 50% water) for 30 min at room temperature (RT) with gentle 
shaking and destained using destaining buffer 1 (60% water, 10% acetic acid and 30% 
methanol) for 1 h at RT with gentle shaking. Each lane was sliced into 6 pieces with a 
surgical blade and placed into a  fresh Eppendorf tube. Then, slices were further 
destained 3 times using destaining buffer 2 (50% acetonitrile (ACN), 20% ammonium 
bicarbonate and 30% milliQ water) by adding 200 μl of buffer to the gel slice, and 
incubating at 37°C for 45 min. Supernatants were discarded and, finally, gel slices were 
dried in a speedivac (LabGear, Australia) on low/high medium heat (< 45°C). One hundred 
(100) µl of reduction buffer (20 mM dithiothreitol, 25 mM ammonium bicarbonate) was 
added to each dried slice, incubated at 65°C for 1 h and supernatants were discarded. 
Alkylation was achieved by adding 100 µl of alkylation buffer (50 mM iodoacetamide, 
25 mM ammonium bicarbonate) to each gel slice, which were further incubated in darkness 
for 40 min at RT. Gel slices were washed with 200 µl of wash buffer (25 mM ammonium 
bicarbonate) and incubated at 37°C for 15 min twice after the gel slices were dried in a 
speedivac. For trypsin digestion, a total of 2 µg of trypsin (Sigma-Aldrich, USA) was 
added to each gel slice and incubated for 5 min at RT. Finally, 50 µl of trypsin reaction 
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buffer (40 mM ammonium bicarbonate, 9% ACN) was added to gel slices and incubated 
overnight at 37°C.  
2.2.6.2. Peptide extraction, cleaning and purification 
Supernatants containing digested peptides were obtained from each sample and placed 
in new Eppendorf tubes. Then, 50 µl of 0.1% trifluoroacetic acid (TFA) in 50% ACN 
was added to gel slices to recover extra peptides following an incubation at 37°C for 
45 min. Supernatants were combined with their corresponding fractions containing the 
digested peptides obtained before, dried in a speedivac and kept at -20°C for desalting.  
Before mass spectrometry analysis, samples were desalted as follows. Peptides were 
resuspended with 10 µl of equilibration buffer (0.1% TFA), applied to a C18 ZipTip® column 
(Merck Millipore, USA), washed several times using 0.1% TFA and eluted with 5 µl of elution 
solution (0.1% TFA, 50% ACN). Eluted peptides were dried in a speedivac and kept at -20°C 
until needed. 
2.2.6.3. Mass spectrometry  
Each sEV fraction and m/lEVs were reconstituted in 10 μl of 5% formic acid, added onto a 50 
mm 300 μm C18 trap column (Agilent Technologies, USA). The samples were then desalted 
for 5 min at 30 μl/min using 0.1% formic acid and the peptides were then eluted onto an 
analytical nano-HPLC column (150 mm × 75 μm 300SBC18, 3.5 μm, Agilent Technologies, 
USA) at a flow rate of 300 nL/min. Peptides were separated using a 95 min gradient of 1–40% 
buffer B (90/10 ACN/0.1% formic acid) followed by a steeper gradient from 40 to 80% buffer 
B in 5 min. A 5600 ABSciex mass spectrometer operated in information-dependent acquisition 
mode, in which a 1 s TOF-MS scan from 350–1400 m/z was used, and for product ion ms/ms 
80–1400 m/z ions observed in the TOF-MS scan exceeding a threshold of 100 counts and a 
charge state of +2 to +5 were set to trigger the acquisition of product ion. Analyst 1.6.1 
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(ABSCIEX, Framingham, MA, USA) software was used for data acquisition. Due to scarcity 
of the S. haematobium ES materials, EVs samples were analysed by mass spectrometry once 
2.2.6.4. Database search and protein identification 
All .wiff files acquired by Analyst 1.6.1 were converted into .mgf format files using 
MSConvert [234] and default settings. For database search and protein identification, a 
database was built using a concatenated target/decoy version of the S. haematobium predicted 
proteome downloaded from Parasite Wormbase (www.parasite.wormbase.org) [235, 236] and 
concatenated to the common repository of adventitious proteins (cRAP, 
https://www.thegpm.org/crap/), 116 sequences). Database search was performed using a 
combination of four search engines (X! Tandem version X! Tandem Vengeance (2015.12.15.2) 
[237], MS-GF+ version Release (v2018.04.09) [238], OMSSA [239] and Tide [240]) using 
SearchGUI version v3.3.3 [241]. The identification settings were as follows: Trypsin, Specific, 
with a maximum of 2 missed cleavages 10.0 ppm as MS1 and 0.2 Da as MS2 tolerances; fixed 
modifications: Carbamidomethylation of C (+57.021464 Da), variable modifications: 
Deamidation of N (+0.984016 Da), Deamidation of Q (+0.984016 Da), Oxidation of M 
(+15.994915 Da). Peptides and proteins were inferred from the spectrum identification results 
using PeptideShaker version 1.16.38 [241]. Peptide Spectrum Matches (PSMs), peptides and 
proteins were validated at a 1.0% False Discovery Rate (FDR) estimated using the decoy hit 
distribution. Only proteins having at least two unique peptides were considered as identified.  
2.2.6.5. Bioinformatic analysis of extracellular vesicles of Schistosoma haematobium 
proteomic data 
Protein family (Pfam) domains were classified using HMMER v3.1b1 [242] as follows. The 
full sequences of the proteins were obtained using the accession numbers of proteins from the 
PeptideShaker. The identified proteins were analysed by HMMER v3.1b1 using the Pfam 
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database (https://pfam.xfam.org/help) [243]. Then, proteins containing Pfam domains with an 
E-value < 1E-05 were selected. The most predominant protein domains were identified for both 
sEVs and m/lEVs by counting the numbers of proteins containing one or multiple copies of a 
specific domain.  
Protein gene ontology (GO) categories were classified using Blast2GO v5.2 [244] as follows. 
A fasta file containing identified proteins was loaded into Blast2GO and blast was performed 
against NCBI  non-redundant database [245]. Functional analysis of protein sequences was 
performed using InterPro. Mapping was used to retrieve GO terms associated to the hits 
obtained by the BLAST. GO terms were selected from the GO pool obtained from mapping 
and query sequences were assigned using annotation. The relationship between GO terms from 
different GO categories was performed using Annex. Finally, integrated annotation result was 
produced by merging GO terms with GO annotations. ReviGO was used to visualise GO terms 
using semantic similarity-based scatterplots [246] as follows. The GO terms from Blast2GO 
were exported and parent GO terms were filtered out to avoid redundancy. Children terms with 
their Nodescore were loaded to http://revigo.irb.hr/ and analysed using default parameters.   
Fasta files of each amino acid sequence were interrogated with TMHMM software [247] for 




2.3.1. Density, protein concentration, particle concentration and purity of small EVs and 
medium/large EVs from Schistosoma haematobium 
S. haematobium adult worm sEVs were purified using ODP. The density of the 12 sEVfractions 
obtained after gradient ranged from 1.039 to 1.4 g/ml (Table 2.1). Protein concentration of each 
sEV fraction and m/lEVs was measured by Bradford assay and the size and concentration were 
determined using a qNano. The protein and particle concentration of the 12 sEV fractions 
ranged from 1.6 to 25.35 µg/ml and 3.72´106 to 1.90´108 particles/ml, respectively, while the 
protein and particle concentration of m/lEVs was 18 µg/ml and 1.08´107 particles/ml, 
respectively. The size of the 12 sEV fractions ranged from 135 nm ± 19.3 to 342 nm ± 113.9 
and size of m/lEVs was 249 nm ± 22.7. sEV fractions having an appropriate purity and density 
[24] (fractions 5–9) were selected for further analysis (Fig. 2.1). sEV fractions 6 and 9 












Table 2.1. Density, protein concentration, particle concentration and purity of Schistosoma 
haematobium adult worm medium/large EVs and small EV fractions after purification by 
















1 1.039 5.29 2.26´107  4.27´106  190 nm ± 27.2 
2 1.04 1.6 5.31´107 3.32´107  216 nm ± 14.4 
3 1.05 1.8 6.96´107  3.72´107  135 nm ± 19.3 
4 1.06 3.4 3.72´106  1.09´106  150 nm ± 29.9 
5 1.07 3.29 9.13´107  2.77´107  136 nm ± 12.4 
6 1.08 8.4 1.90´108  2.26´107  146 nm ± 11.3 
7 1.08 8.09 9.58´107  1.18´107  153 nm ± 10.2 
8 1.13 8.69 8.91´107  1.02´107 173 nm ± 19.3 
9 1.16 11.64 1.21´108 1.04´107 191 nm ± 27.4 
10 1.24 18.86 1.53´108 7.95´106     342 nm ±113.9 
11 1.29 25.35 6.20´107 2.44´106 310nm ± 103.2 
12 1.4 23.35 1.02´107 4.36´105 233 nm ± 77.5 






















Figure 2.1. Tunable resistant pulse sensing analysis of small EVs and medium/large EVs from 
Schistosoma haematobium. Size and number of EVs secreted by S. haematobium was analysed by 
qNano (iZon). A) Size and concentration of particles in sEV-containing fractions (5-9). B) Size and 








































2.3.2. Proteomic analysis of small EVs and medium/large EVs from Schistosoma 
haematobium 
The proteome composition of S. haematobium adult worm EVs was characterised by LC-
MS/MS. After combining the results from fractions 5-9 (fractions containing the highest purity 
of sEVs), a total of 133 proteins matching S. haematobium proteins and common contaminants 
from the cRAP database were identified. From these, 80 proteins were identified with at least 
two validated unique peptides and 57 of them matched S. haematobium proteins. From the 57 
identified proteins, 8 (14%) contained a transmembrane domain and 7 (12%) had a signal 
peptide. Similarly, 509 proteins were identified from m/lEVs. From these, 346 proteins were 
identified with at least two validated unique peptides and 332 matched S. haematobium 
proteins. From these identified proteins, 54 (16%) contained a transmembrane domain and 26 
(8%) had a signal peptide. Forty proteins were identified in both sEVs and m/lEVs. The identity 
of the most abundant proteins and proteins typically found in other helminth EVs are shown in 
table 2.2. 
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Table 2.2. List of proteins found only in each type of Schistosoma haematobium extracellular vesicle. 
Protein location Protein identity Protein accession numbers 
sEVs Proteasome subunit MS3_10249.1, MS3_05734.1, MS3_01483.1, MS3_06009.1, MS3_04526.1, 
MS3_08808.1, MS3_07240.1, MS3_02807.1, MS3_09236.1 and MS3_03070.1 
 GAPDH MS3_10141.1 
 Papain family cysteine protease  MS3_08498.1 
 C-terminal domain of 1-Cys 
peroxiredoxin 
MS3_08460.1 




Cytosol amino peptidase MS3_01749.1 
Trefoil (P-type) domain-containing 
protein  
MS3_00004.1 
sEVs and m/lEVs TSPs  MS3_09198, Sh-TSP-2, MS3_05226, MS3_05289 and MS3_01153 
Ferritin-like domain  MS3_07972.1 and MS3_07178.1 
14-3-3 protein  MS3_03977.1 and MS3_00047.1 
Elongation factor Tu C-terminal 
domain  
MS3_08479.1 
EF hand  MS3_08446.1 
Actin  MS3_07374.1 
GST, N-terminal domain  MS3_06482.1 
Cytosol aminopeptidase family, 
catalytic domain  
MS3_08450.1 
Lipocalin / cytosolic fatty-acid 
binding protein family  
MS3_04307.1 
Immunoglobulin domain  MS3_03208.1 
Saposin-like type B, region 2  MS3_02805.1 
Enolase, N-terminal domain  MS3_02425.1 
m/lEVs EF hand MS3_05735.1, MS3_00180.1, MS3_09846.1, MS3_05877.1, MS3_05317.1, 
MS3_04536.1, MS3_10043.1, MS3_05959.1, MS3_05150.1, MS3_04275.1, 
MS3_05958.1 MS3_05952.1, MS3_00361.1 and MS3_02003.1 
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Ras family MS3_10193.1, MS3_05953.1, MS3_05910.1, MS3_05976.1, MS3_07854.1, 
MS3_11139.1, MS3_02375.1, MS3_01653.1, MS3_04355.1, MS3_09110.1, 
MS3_09593.1 and MS3_03443.1 
TCP-1/cpn60 chaperonin family MS3_03054.1, MS3_06928.1, MS3_01627.1, MS3_10572.1, MS3_06669.1, 
MS3_07556.1, MS3_08399.1, MS3_00785.1 and MS3_08926.1 
TSPs MS3_01905.1 and MS3_01370  
Heat-like repeat MS3_08696.1, MS3_01642.1, MS3_09658.1, MS3_10590.1, MS3_05814.1, 
MS3_02928.1 and MS3_06293.1 
Calponin homology (CH) domain MS3_07481.1, MS3_05505.1, MS3_01744.1, MS3_00852.1, MS3_00361.1, 
MS3_03766.1 and MS3_10701.1 
Dynein light chain type 1 MS3_05351.1, MS3_08569.1, MS3_05345.1, MS3_01173.1, MS3_05342.1, 
MS3_04412.1 and MS3_05960.1 
Actin MS3_07374.1, MS3_04014.1, MS3_00351.1, MS3_02465.1, MS3_04907.1 and 
MS3_01922.1 
HSP-70 protein MS3_10713.1, MS3_11293.1, MS3_11411.1, MS3_10049.1, MS3_02688.1 and 
MS3_02787.1 
Immunoglobulin domain MS3_03027.1, MS3_01271.1, MS3_03208.1, MS3_07594.1 and MS3_01223.1 
Annexin MS3_08725.1, MS3_08723.1, MS3_04598.1, MS3_01964.1 and MS3_01952.1 
AAA domain MS3_03802.1, MS3_02581.1, MS3_01139.1, MS3_01650.1 and MS3_07031.1 







2.3.3. Protein families present in Schistosoma haematobium small EVs and medium/large 
EVs 
Identified proteins were subjected to a Pfam analysis using default parameters in HMMER 
v3.1b1 and proteins containing an identified Pfam domain with a E< 1E-05 were selected. A 
total of 70 and 387 domains were identified from sEVs and m/lEVs, respectively. In sEVs, the 
three most abundant domains were proteasome subunit domains (PF00227) (14%), TSP family 
domains (PF00335) (7%) and ferritin-like domains (PF12902) (4%) (Fig. 2.2A). The most 
abundant protein domains from m/lEVs were EF-hand domains (PF00036) (3%), Ras family 
domains (PF00071) (3%), TCP-1/cpn60 chaperonin family domains (PF00118) (2%) and TSP 
family domains (PF00335) (2%) (Fig. 2.2B). From these, TSP family domains, ferritin-like 


































Figure 2.2. Pfam analysis of the most abundant Schistosoma haematobium vesicle proteins. X-axis 
represents the number of proteins containing at least one of those domains. (A) sEVs (B) m/lEVs. 
2.3.4. Gene ontology terms of Schistosoma haematobium small EVs and medium/large EV 
proteins  
The proteins of adult S. haematobium sEVs and m/lEVs were annotated using Blast2GO [244]. 
In sEVs, Blast2GO returned at least one biological process, molecular function or cellular 
function term for 70%, 81% and 65% of proteins, respectively.  In m/lEVs, Blast2GO returned 







and 48% of proteins, respectively. To avoid redundancy in the analysis and for a better 
comprehension of the represented GO terms in the sEVs and m/lEVs, the parental GO terms 
were removed. In sEVs, after removal of parental redundancy, 11, 9 and 7 GO terms belonging 
to biological processes, molecular function and cellular component, respectively, were 
identified. Similarly, for m/lEVs, 12, 4 and 8 GO terms belonging to biological processes, 
molecular function and cellular component, respectively, were identified. These children GO 
terms were visualised using ReviGO based on semantic similarity-based scatterplots [246]. The 
GO terms were ranked by the nodescore provided by Blast2GO and plotted using their 
nodescore and frequency. Semantically similar GO terms plot close together and increasing 
heatmap score signifies increasing nodescore from Blast2GO. The circle size denotes the 
frequency of the GO term from the underlying database. In sEVs, several biological processes 
were highly represented, such as the ubiquitin-dependent protein catabolic process, oxidation-
reduction process and gluconeogenesis and glycolytic process (Fig. 2.3A). Similarly, in 
m/lEVs, several biological processes were highly represented, such as the carbohydrate 
metabolic process, transport process, organonitrogen compound metabolic process and 
microtubule-based process (Fig. 2.3B). Oxidation-reduction process was common to both sEVs 


























Figure 2.3. Biological process GO term categories of adult Schistosoma haematobium vesicle proteins. 
Biological processes were ranked by nodescore (Blast2GO) and plotted using REViGO. Semantically 
similar GO terms plot close together, increasing heatmap score signifies increasing nodescore from 
Blast2GO, while circle size denotes the frequency of the GO term from the underlying database. (A) 








In sEVs, several molecular functions were highly represented, such as threonine-type 
endopeptidase activity, protein binding activity, endopeptidase activity and transition metal ion 
binding activity (Fig. 2.4A). In m/lEVs, molecular functions such as protein binding activity, 
ATP binding activity, nucleoside-triphosphatase activity and calcium ion binding activity were 
highly represented (Fig. 2.4B). From these highly represented molecular function terms, 
protein binding was common to both sEVs and m/lEVs, with 5 proteins from sEVs and 83 
proteins from m/lEVs being involved in this process. All 5 sEV proteins involved in protein 






































Figure 2.4. Molecular function GO term categories of adult Schistosoma haematobium vesicle proteins. 
Molecular functions were ranked by nodescore (Blast2GO) and plotted using REViGO. Semantically 
similar GO terms plot close together, increasing heatmap score signifies increasing nodescore from 
Blast2GO, while circle size denotes the frequency of the GO term from the underlying database. (A) 







The most highly represented cellular component terms in sEVs were proteins associated with 
nucleus, integral component of membrane, non-membrane-bounded organelle and proteasome 
core complex (alpha-subunit complex) (Fig. 2.5A) and the most abundant cellular component 
terms in m/lEVs were proteins associated with integral component of membrane, cytoskeletal 
part, cytoplasmic part and non-membrane-bounded organelle (Fig. 2.5B). Integral component 
of membrane, cytoplasmic part and non-membrane-bounded organelle terms were common to 
both sEVs and m/lEVs. In sEVs and m/lEVs, 9 and 83 proteins, respectively, were integral 
membrane proteins. From sEVs, 5 TSPs are integral membrane proteins whereas in m/lEVs 7 
TSPs and calpain large subunit domain are integral membrane proteins. In m/lEVs, 33 proteins 




































Figure 2.5. Cellular component GO term categories of adult Schistosoma haematobium vesicle 
proteins. Cellular components were ranked by nodescore (Blast2GO) and plotted using REViGO. 
Semantically similar GO terms plot close together, increasing heatmap score signifies increasing 
nodescore from Blast2GO, while circle size denotes the frequency of the GO term from the underlying 








This study showed that S. haematobium secretes at least two populations of vesicles (m/lEVs 
and sEVs) with a clear difference in size and proteomic composition. After separating them 
from m/lEVs, the sEV fractions were further fractionated by ODP to isolate pure vesicles by 
reducing contamination from soluble proteins [24]. The size of the purified sEVs ranged from 
136 nm ± 12.4 to 191 nm ± 27.4, while in S. mansoni, the size of sEVs ranged from 77.4 nm ± 
34.8 to 97.9 nm ± 28.5 [24]. The size of F. hepatica sEVs ranged from 30-100 nm [118], while 
in the nematode, A. suum, T. muris and N. brasiliensis, their size ranged from 80 nm to 200 
nm, 93 nm ± 41.5 to 165 nm ± 54.9 and 60 nm to 160 nm [122, 123, 126], showing the 
heterogenicity of EV size between helminths. 
Only a fraction of proteins from sEVs and m/lEVs were predicted to contain signal peptides or 
transmembrane domains, in agreement with similar reports from O. viverrini, S. mansoni, N. 
brasiliensis and T. muris [24, 117, 122, 123]. The presence of many proteins without signal 
peptides and transmembrane domains indicates the role of vesicles in the release of these 
leaderless proteins into the external environment [249].  
The most represented domains contained within sEV proteins were the proteasome subunit 
domains, TSP domains, ferritin-like domains, cytosol aminopeptidase family catalytic domains 
and 14-3-3 protein domains. The proteasome is involved in the biogenesis of EVs [250] and 
also controls protein homeostasis and degradation of damaged proteins [251]. Furthermore, in 
schistosomes, the proteasome plays an important role in the cellular stress response and 
survival of the parasite [252]. For example, treating mice with a proteasome inhibitor and 
infecting with S. mansoni cercariae significantly impaired parasite development [253], and 
treating schistosomula in vitro with siRNAs targeting a deubiquitinase subunit of the 19S 







targeted in vaccine strategies; immunisation of mice with S. japonicum a5-subunit proteasome 
stimulated a strong antibody response and significantly reduced adult worm and egg burden in 
the subsequent challenge [255]. 
Ferritins are iron-storage proteins, involved in maintaining intracellular iron balance [256]. 
This activity of ferritins minimizes free-radical reactions and prevents cellular damage caused 
by iron accumulation in the cell [257]. Iron also plays an important role in eggshell formation 
of schistosomes and fer-1 is highly expressed in female worms in comparison to males [258]. 
Since, female worms produce many eggs per day and eggs are the primary cause of pathology, 
vaccination using ferritins could disrupt the formation of eggs and reduce egg-induced 
pathology [259]. Indeed, ferritins have been tested as vaccine candidates against schistosomes; 
immunisation of mice with the recombinant Fer-1 of S. japonicum caused 35.5% and 52.1% 
reduction in adult worm and liver egg burden, respectively [260]. Besides their role as vaccines, 
ferritins could also be drug targets for iron chelators in parasitic infection [261], and iron 
chelators have been shown to halt the growth of schistosomes and protozoan parasites in vitro 
[262, 263]. Ferritins have been identified in the proteomic analysis of other blood feeding 
helminths EVs [24, 118], suggesting a role for EVs in iron acquisition.  
In helminths, aminopeptidases cleave peptides to free amino acids before being distributed to 
the internal tissues of the parasite [264]. They are also involved in the egg hatching process of 
schistosomes [265] as RNAi-mediated silencing of S. mansoni egg aminopeptidase 
significantly decreased hatching [266]. Moreover, aminopeptidases have been tested as vaccine 
candidate antigens against F. hepatica infection in animal models; immunisation of sheep with 
native and recombinant leucine aminopeptidases resulted in 49-89% adult worm reduction in 
subsequent F. hepatica challenges [185, 186]. Interestingly, this vaccine candidate was also 







the presence of these proteolytic enzymes within the EVs of S. haematobium and other 
helminths suggests the involvement of EVs in nutrient acquisition processes. 
From GO analysis, the most represented cellular component of sEV proteins was the nucleus 
and integral component of membrane. This is consistent with the pfam analysis of sEVs, in 
which proteasome subunit-containing proteins, the most abundant protein family, is formed 
from the internal parts of the cell, whereas TSPs, the second most abundant protein family, is 
an integral component of the EV membrane. This supports the idea that sEVs are formed from 
endosomes and discharged when the MVB blends with the cell membrane [96] as occurs in 
other organisms [118].  
The second and fourth most abundant protein domains in sEVs and m/lEVs, respectively, were 
the TSPs. TSPs are involved in EV biogenesis [97] and they are present on the surface 
membrane of EVs from many different organisms and are considered a molecular marker of 
EVs [267]. TSPs are also found from the proteomic analysis of other helminth EVs [24, 25, 
117-123]. In trematodes, TSPs are involved in tegument development [157-159] and in 
schistosomes, TSP LELs have been tested as vaccine candidates [160, 161, 268]. Furthermore, 
antibodies produced against TSPs present in O. viverrini EVs blocked the internalisation of 
EVs by cholangiocytes and decreased pathogenesis [117, 160]. TSPs from other platyhelminths 
such as Taenia solium and S. japonicum are immunogenic and have potential as diagnostic 
candidates [157, 159, 231, 269-271].  
The most represented domains in S. haematobium m/lEVs were EF-hand, Ras family, TCP-
1/cpn60 chaperonin family, TSP family, heat-like repeat, calponin homology (CH), dynein 
light chain type 1 and actin domains. Proteins containing EF-hand domains are involved in a 
number of protein-protein interactions for the uptake and release of calcium [272]. The influx 
of calcium in the cell induces the redistribution of the phospholipids of cell membrane resulting 







protein domains found within other helminths EV proteins [117]. This is also in line with the 
GO analysis, in which proteins involved in protein binding and calcium ion binding are the 
highest represented molecular function terms. Ras proteins serve as signalling nodes activated 
in response to diverse extracellular stimuli [274] and Ras proteins are involved in biogenesis 
and release of m/lEVs [97]. In S. mansoni, Ras proteins are involved in the male-directed 
maturation of the female worms [275], which could suggest a potential role of EVs in parasite-
parasite communication. TCP-1/cpn60 chaperonin family proteins play an important role in the 
folding of proteins, including actin and tubulin [276], which bind and hydrolyse ATP using 
magnesium ions [277]. This is consistent with the molecular function GO terms, in which, ATP 
binding and nucleoside-triphosphatase was the most represented. The calponin homology (CH) 
domain is an actin-binding protein playing a major regulatory role in muscle contraction [278]. 
Contraction of cytoskeletal structures by actin–myosin interactions completes vesicle 
formation [100] and the presence of actin together with calponin helps the contraction of the 
membrane that facilitates the release of m/lEVs [97]. Dynein is involved in the transport of 
vesicles and organelles, as well as positioning the mitotic spindle and microtubule organizing 
centres with respect to the cell cortex [279]. This is also in line with the GO analysis of m/lEVs, 
in which transport is one the highest represented biological process terms.  
The proteomic analysis S. haematobium EVs (sEVs and m/lEVs), revealed many proteins 
involved in host-parasite interactions. Some of these proteins were homologues of other 







Chapter 3: Characterisation of tetraspanins from Schistosoma 
haematobium extracellular vesicles 
3.1. Introduction 
In chapter 2, the proteomic composition of S. haematobium adult worms EVs was 
characterised, revealing many different proteins, including TSPs. TSPs are a family of proteins 
expressed in many organisms [156] and involved in many biological processes, including 
membrane organisation [147], modulation of immunity [280] and cancer progression [281]. 
The first member of the TSP family to be identified in humans was CD81 [282]; since then, 
this family of proteins has been extensively studied in other organisms. To date, a total of 33, 
37 and 20 different TSPs have been found in mammals, Drosophila melanogaster and 
Caenorhabditis elegans, respectively [151].  
In parasitic helminths, TSPs are involved in host-parasite interactions and some of them are 
being tested as potential vaccines (reviewed in chapter 1.3.1.2.1) and diagnostic candidates 
[160, 161, 163, 268-270]. Sm23 was the first TSP reported from schistosomes [149] and, 
thereafter, other TSPs from S. mansoni and S. japonicum have been identified and characterised 
[161, 283-285]. In addition to their presence in the tegument of helminths [17, 157, 159, 161, 
286], TSPs have also been found on the membrane of EVs from many of helminths (including 
F. hepatica, T. muris, S. mansoni, O. viverrini, S. japonicum, E. multilocularis, E. granulosus 
and N. brasilensis [24, 25, 117-123]) and are considered a molecular marker of exosomes 
[267]. Antibodies produced against TSPs present in the membrane of O. viverrini EVs blocked 
the internalization of EVs by cholangiocytes and decreased the production of cytokines that 
initiate the pathogenesis [117, 160]. Although TSPs are well characterised in other 







study aimed to characterise Sh-TSPs found from the proteomic analysis of adult worm EVs in 
terms of their potential as vaccine and diagnostic candidates for the control of urogenital 
schistosomiasis.  
There are 19 Sh-TSPs encoded in S. haematobium genome and, from these, 7 of them were 
found in S. haematobium EVs. Herein, I have selected a total of six Sh-TSPs that might be 
playing key roles in host-parasite interactions based on their presence in S. haematobium adult 
EVs. The expression level of each Sh-TSP in different stages of the parasite was analysed by 
qPCR and the anatomic sites of expression in adult worms was assessed using antibodies raised 








3.2. Materials and methods 
3.2.1. Experimental animals  
Male BALB/c mice were purchased and maintained at the AITHM animal facilities on the 
Cairns campus as discussed previously (chapter 2.2.1). All experimental procedures 
performed on animals in this study were approved by the James Cook University (JCU) 
animal ethics committee (ethics approval number A2391 and A2395). 
3.2.2. Schistosoma haematobium material  
Adult S. haematobium worms were obtained as previously described (chapter 2.2.3). Freshly 
perfused S. haematobium adult worms were fixed in paraformaldehyde, embedded in paraffin 
and cryostatically sectioned into 7.0 µm sections [287]. 
S. haematobium cercariae were mechanically transformed into schistosomula as described 
previously [233]. Schistosomula were resuspended to a density of 1,000/ml in modified Basch 
media supplemented with 4x antibiotic-antimycotic and incubated at 37°C in 5% CO2. Media 
was changed daily and schistosomula (1,000) collected at 24 h, 3 and 5 days and immediately 
stored in 500 μl of TRI reagent (Sigma-Aldrich, USA) at -80°C until further use. 
3.2.3. RNA extraction, cDNA synthesis and real time quantitative PCR (RT-qPCR) 
Total RNA from S. haematobium schistosomula (24 h, 3 and 5 days) was extracted using TRI 
reagent as per manufacturer’s instructions. The RNA pellet was finally resuspended in 12 μl of 
RNAse-free water and incubated for 5 min at 55°C. First strand cDNA was synthesized using 
superscript III (Invitrogen, USA) and 11 µl of RNA according to manufacturer’s instructions. 








RT-qPCR was performed to determine the expression levels of S. haematobium TSP-encoding 
genes in different life stages (adult, egg, miracidia, cercaria and schistosomula (24 h, 3 days 
and 5 days)). Each qRT-PCR reaction consisted of 5 µl of SYBR premix EX Taq (2x) 
(Qiagen, Netherlands), 1 µl (10 mM) of each forward and reverse primer (Appendix Table 
1), 1 µl (50 ng) of the first–stand cDNA and sterile water to a final volume of 10 µl. The 
reactions were performed on a Rotor-Gene Q (Qiagen, Netherlands) using the following 
conditions: initial denaturation at 95°C for 10 min (1 cycle) followed by 40 cycles of 
denaturation (95°C for 10 sec), annealing (50°C for 15 sec) and extension (72°C for 20 sec). 
S. haematobium tsp expression was normalised to a housekeeping gene (a-tubulin, accession 
number XM_012938434.1) as described before [288] and relative expression levels were 
calculated using the 2−ΔΔCt method using eggs as a reference group [289].  
3.2.4. Phylogenetic analysis  
A phylogenetic analysis was performed on the 19 Sh-TSPs and 32 well-characterised TSPs 
from different organisms (Bos taurus, Danio rerio, Homo sapiens, Mus musculus, S. 
japonicum, S. mansoni and O. viverrini) belonging to 3 different groups of TSP families 
(uroplakin, CD81/CD9 and CD63). The sequences of these TSPs were obtained from the NCBI 
database. A multiple sequence alignment was carried out using the alignment program MAFFT 
(v7.271) [290].  Outliers with poor alignment (long unaligned regions) were detected and 
filtered out using ODSeq v1.0 
(https://bioconductor.org/packages/release/bioc/html/odseq.html) resulting in the removal of 
two sequences (XP_012793320 and XP_012797041). PhyML (v20160207) [291] was used for 
maximum-likelihood (ML) phylogenetic analyses of the amino acid sequences using default 
parameters. The tree was visualised with The Interactive Tree of Life (iTOF) online phylogeny 







3.2.5. Cloning of Schistosoma haematobium tetraspanins 
The cDNAs encoding for the open reading frames of the 5 Sh-tsps (ms3_09198, ms3_01370, 
ms3_01153, ms3_05226 and ms3_05289) were obtained from the cDNA library of S. 
haematobium (www.parasite.wormbase.org), while the cDNA encoding for the open reading 
frame for Sh-tsp-2 was obtained from Genbank (accession number MK238557). The LEL 
regions from the 6 Sh-TSPs were identified using Tmpred (https://embnet.vital-
it.ch/software/TMPRED_form.html) and amplified by PCR using oligonucleotide primers 
flanking these regions and S. haematobium adult cDNA as a template. The PCR reaction was 
performed as follows: 2 µl (50 ng) adult worm cDNA, 3 µl (10 µM) each of forward primer 
and reverse primer (Appendix Table 2), 10 µl MyTaq red reaction buffer (Bioline, UK), 31.5 
µl water and 0.5 µl MyTaq DNA polymerase (Bioline, UK). The PCR cycling conditions 
followed an initial cycle of denaturation at 95°C for 5 min, 35 cycles of denaturation at 95°C 
for 15 sec, annealing at 50°C for 15 sec and extension at 72°C for 30 sec and a final 
extension step at 72°C for 7 min. Finally, the PCR products of ms3_09198, ms3_01370, 
ms3_01153, ms3_05226 and ms3_05289 were NcoI/XhoI cloned into pET-32aΔHis such that 
they were in frame with the N-terminal thioredoxin (TrX) and C-terminal 6xHis tags. The 
vector pET-32aΔHis is an in-house modified version of pET-32a (Novagen, USA) which has 
the N-terminal 6XHis-tag absent to facilitate efficient purification after cleavage of the TrX 
tag. The Sh-tsp-2 PCR product was NdeI/XhoI cloned into pET41a (Novagen, USA) to 
facilitate native N-terminal expression without the GST fusion tag but retaining the C-terminal 
6xHis tag. Recombinant vectors were transformed into E. coli TOP10 strains (ThermoFisher 







3.2.6. Protein expression  
Plasmids (pET32a recombinants) were transformed into E. coli BL21(DE3) (ThermoFisher 
Scientific, USA) and resultant colonies were inoculated into 10 ml of Luria broth containing 
100 μg/ml ampicillin (LBamp) and incubated overnight at 37°C with shaking at 200 rpm. 
Overnight culture was seeded (1/100) into 500 ml of fresh LBamp and incubated at 37°C with 
shaking at 200 rpm until OD600 = 0.5-1 (approximately 3 h), whereupon expression was 
induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) (Bioline, UK). 
Cultures continued incubating for 4 h (MS3_09198, MS3_01370, MS3_05226, MS3_01153) 
or 16 h (MS3_05289) and were then harvested by centrifugation at 8,000 ´g for 20 min at 4°C. 
Sh-TSP-2 was expressed as for MS3_01370 except that LB supplemented with 50 μg/ml 
kanamycin was used instead of LBamp. 
Each harvested pellet was resuspended in 50 ml of lysis buffer (50 mM sodium phosphate pH 
8, 40 mM imidazole and 300 mM NaCl), freezed/thawed 3 times and then sonicated 10 times 
(5 s bursts) at 4°C. Then, for the soluble proteins (Sh-TSP-2, MS3_09198 and MS3_01370 – 
determined by a small-scale pilot expression) the bacterial lysate was centrifuged at 20,000 ´g 
for 20 min at 4°C and the supernatant decanted and stored at -80°C. In the case of insoluble 
proteins (MS3_01153, MS3_05226 and MS3_05289 – determined by small-scale pilot 
expression), Triton X-100 was added to a final concentration of 3% after sonication, the 
mixture incubated for 1 h at 4°C with gentle shaking and then pelleted at 20,000 ´g for 20 min 
at 4°C. The supernatant was removed, the pellet washed twice with 30 ml of lysis buffer (with 
centrifugation at 20,000 ´g for 20 min at 4°C after each wash) and the final pellet resuspended 
in 20 ml of solubilisation buffer (50 mM sodium phosphate, 40 mM imidazole, 300 mM NaCl 
and 6 M urea). The resuspension was incubated at 4°C overnight with gentle shaking, 







3.2.7. Protein purification  
Recombinant proteins were purified by Ni2+ IMAC using an AKTA Prime UPC FPLC (GE 
Healthcare, USA). Each recombinant protein solution was diluted 1:4 in buffer A (1x PBS, 300 
mM NaCl (soluble proteins) or 1x PBS, 300 mM NaCl and 6 M urea (insoluble proteins) pH 
8) and filtered through a 0.45 μm filter. The solutions were then applied to a 1 ml His-Trap 
IMAC column (GE Healthcare, USA), equilibrated with buffer A (1x PBS, 300 mM NaCl 
(soluble proteins) or 1x PBS, 300 mM NaCl and 6 M urea (insoluble proteins) pH 8), at a flow 
rate of 1 ml/min. Bound proteins were washed with 10 column volume of buffer A for both 
soluble proteins or insoluble proteins and then eluted with an increasing linear gradient of 
imidazole (100-500 mM). Fractions containing purified recombinant proteins were combined 
and buffer exchanged into PBS (soluble proteins) or (1x PBS, 300 mM NaCl and 6 M urea) 
(insoluble proteins) using a 3 kDa MWCO Amicon Ultra-15 centrifugal filter. The identity of 
expressed proteins was confirmed by SDS-PAGE and Western blot using anti-His monoclonal 
antibodies. 
3.2.8. Polyclonal antibody production 
Three male BALB/c mice (6 weeks old) were immunised subcutaneously with 50 µg of 
recombinant protein emulsified with an equal volume of alum adjuvant (Thermo Fisher 
Scientific, USA) and boosted twice at two weekly intervals using same amount of protein as 
described previously [287]. Blood was collected from each mouse before immunisation and 
two weeks after the final immunisation. Sera was collected by allowing the blood to clot 
followed by centrifugation at 10,000 ´g for 10 min and storage at -20°C. 
3.2.9. Immunohistochemistry  







expression in adult worm sections. Adult worm sections from S. haematobium were de-
paraffinized using 2 x 3 min washes each of 100% and 50% xylene and rehydrated in an ethanol 
series. Antigen retrieval was performed by boiling the slides in citrate buffer (10 mM sodium 
citrate, pH 6) for 40 min followed by Tris buffer (10 mM Tris, 1 mM EDTA, 0.05% Tween, 
pH 9.0), for 20 min. Subsequently, sections were blocked with 10% goat serum for 1 h at RT. 
After washing 3 times with TBS/0.05% Tween-20 (TBST), sections were incubated with anti- 
Sh-TSP antisera (diluted 1:50 in 1% BSA/TBST) overnight at 4°C and then washed with TBST 
(3 x 5 min). Sections were finally probed with goat-anti-mouse IgG-Alexa Fluor 647 (Sigma-
Aldrich, USA) (diluted 1:200 in 1% BSA/TBST) for 1 h in the dark at RT. After a final washing 
step with TBST, slides were mounted with Entellan mounting medium (Millipore, Germany) 
and covered with coverslips. Images were acquired by Nuance software with an AxioImager 








3.3.1. General characteristics of Schistosoma haematobium tetraspanins 
A total of 19 TSPs were found in the genome of S. haematobium and out of these 7 of them 
were found in the S. haematobium EVs. Then, six Sh-TSPs (MS3_01370, MS3_05289, 
MS3_05226, MS3_09198, MS3_01153 and Sh-TSP-2) were selected based on the results 
obtained from the proteomic analysis of the adult worm EVs as discussed in chapter 2.3.3. 
The sequences of all Sh-TSPs were inspected and all contained four transmembrane domains, 
SEL, LEL and three intracellular regions. For Sh_TSP-2, MS3_09198 and MS3_01370 LEL 
contained four cysteine residues (forming two disulfide bonds) whereas MS3_05226, 
MS3_05289 and MS3_01153 LEL contained six cysteine residues (forming three disulfide 
bonds). All Sh-TSPs contained the CCG motif characteristic of TSPs [281]. Full-length 
cDNA and predicted amino acid sequences are shown in Table 3.1. The amino acid sequence 
identities between the Sh-TSPs described here and their S. mansoni homologs (across the 
entire ORF and the LEL alone) are shown in Table 3.2. Amino acid homology of Sh-TSPs 
with their respective S. mansoni homologs ranged from 83-93% (when entire ORFs were 







Table 3.1. Characteristics of Schistosoma haematobium tetraspanins. LEL: large extracellular loop, SEL: small extracellular loop, bp: base pair, 
kDa: kilodalton. 
TSPs Sh-TSP-2 MS3_05226 MS3_09198 MS3_05289 MS3_01370 MS3_01153 
cDNA length (bp) 660 882 654 888 675 837 
Number of amino acids 219 273 218 295 225 278 
Weight of encoded proteins (kDa) 24.4 30.4 24.2 32.9 24.9 30.9 
SEL position 34-53 31-79 36-56 32-66 36-54 36-76 
Inner loop position 71-88 97-109 72-81 87-95 74-82 100-108 
LEL position 106-184 128-239 103-184 118-266 108-190 130-250 
Cytoplasmic tail 207-219 265-273 205-218 283-295 212-225 272-278 
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Table 3.2. The amino acid sequence percentage identity of Schistosoma haematobium 
tetraspanin open reading frames (ORF) and large extracellular loop (LEL) with their 
respective Schistosoma mansoni homolog. 
Sh-TSPs Sm-homologs % Identity (similarity) with homolog S. mansoni TSPs 
ORF LEL 
MS3_05226 Smp_041460 86 (93) 84 (93) 
MS3_01370 Smp_173150 90 (96) 80 (91) 
MS3_05289 Smp_344440 83 (90) 81 (88) 
MS3_01153 Smp_140000 86 (94) 82 (92) 
Sh_TSP-2 AAN17276 84 (90) 69 (78) 
MS3_09198 AAA73525 93 (95) 84 (88) 
 
3.3.2. Phylogenetic analysis of Schistosoma haematobium tetraspanins  
A phylogenetic analysis between the Sh-TSPs and other well-characterised TSPs from 
related trematodes was performed. Sh-TSP-2, MS3_09198, MS3_01370 and MS3_02232 
grouped together in the CD63 ancestry of the TSP family and clustered together with other 
well characterised CD63-like TSPs from S. mansoni (AAN17276.1, AAA73525 and 
XP_018650438), S. japonicum (CAX70616.1 and AAW26928) and O. viverrini 
(JQ678707.1 and JQ678708.1) (Fig. 3.1). MS3_05289, MS3_05226, MS3_01153, 
MS3_07569, MS3_08458, MS3_01905, MS3-03452, MS3_03944, MS3_01557, 
MS3_03883 and MS3_01094 clustered under the uroplakin family of TSPs, together with 
other TSPs from S. mansoni (XP_018649476 XP_002577444 and XP-002575497) and S. 
japonicum (AAW26326, AAW24822, AAP05954 and AAW27174) (Fig. 3.1). MS3_09789 




Figure 3.1. Phylogenetic analysis of Schistosoma haematobium tetraspanins and homologs from related organisms. A 
multiple sequence alignment was carried out using the Muscle alignment tool. The tree was visualized with The Interactive 
Tree of Life (iTOF) online phylogeny tool (https://itol.embl.de/) using default parameters. NP_991372=CD63 antigen, 
NP_776325.1=CD9 antigen, NP_776907.2=Uroplakin-1b, GAA49954.1=CD9 antigen, NP_955837.1=CD63 
antigen,NP_001003735.1=CD81 antigen, NP_001035332.1=Uroplakin-1a, NP_001771.1=CD63 antigen, 
NP_004347.1=CD81 antigen, NP_008883.2=Uroplakin-1b, NP_031679.1=CD63 antigen, NP_031683.1=CD9 antigen, 
NP_849255.2=Uroplakin-1b, JQ678707.1=Ov-TSP-2,JQ678708.1=Ov-TSP-3, JQ678706.1=Ov-TSP-1, 
XP_012800477.1=MS3_09198,XP_012792774.1=MS3_01153,XP_012796731.1=MS3_05289,XP_012796668.1=MS3_052
26,XP_012792980.1=MS3_01370,CAX70616.1=CD63 antigen, CAX70118.1=CD9/CD37/CD6, AAW26928.1=Sj-TSP-1, 
AAW24822.1=Sj-TSP-2, AAW24863.1= Sj-TSP-3, AAP05954.1= Sj-TSP-4, AAW27174.1= Sj-TSP-5, AAW26326.1=Sj-
TSP-6, AAN17276.1=Sm-TSP-2, XP_002580456.1=Sm-TSP-1, XP_002577444.1=Tspan-1,XP_002575497.1=TSP D76, 
AAA73525.1=Sm23, XP_018649476.1= TSP 18, XP_018650438.1= CD63 antigen-like, XP_018653608= Putative TSP, large 






3.3.3. Protein expression and purification 
The LEL region from each of the Sh-tsps was cloned into a bacterial expression system and 
sequences were validated by Sanger sequencing. The MS3_09198, MS3_01370 and Sh-TSP-
2 LELs were expressed as soluble proteins, while MS3_01153, MS3_05226 and MS3_05289 
were expressed as inclusion bodies and 6 M urea was used for solubilisation. The expected 
sizes of the expressed Sh-TSPs were confirmed by SDS-PAGE (Fig. 3.2A) and a western-
blot using a monoclonal anti-His antibody (Fig. 3.2B). 
Figure 3.2. Coomassie stained SDS-PAGE gel and Western blot analysis of Schistosoma 
haematobium tetraspanins. One µg of each protein was electrophoresed on an SDS-PAGE gel 
and stained with Coomassie blue: (A1) Sh-TSP-2, (A2) MS3_01153, (A3) MS3_05289, (A4) 
MS3_05226, (A5) MS3_09198 and (A6) MS3_01370. A western blot was performed using an 
anti-His monoclonal antibody: (B1) Sh-TSP-2, (B2) MS3_01153, (B3) MS3_05289, (B4) 
MS3_05226, (B5) MS3_09198 and (B6) MS3_01370.  
3.3.4. Schistosoma haematobium tetraspanins are expressed throughout all life stages  
The transcriptional patterns of all Sh-tsps were analysed in different life stages of S. 




time qPCR. All Sh-tsp genes were expressed throughout all life stages tested (Fig. 3.3A-F). 
Sh-tsp-2 expression peaked at 24 h schistosomula and decreased in subsequent 
developmental stages (Fig. 3.3A). Similarly, the highest expression levels of ms3_01370, 
ms3_05226 and ms3_05289 were identified in the miracidia while the lowest levels of 
expression were observed in 3 days schistosomula, adult and 24 h schistosomula, 
respectively (Fig. 3.3B, D, F). In the case of ms3_09198, the highest expression level was 
observed in cercariae and the lowest expression level was observed in miracidia (Fig. 3.3C). 
The expression level of ms3_01153 was highest in cercariae and lowest in adult life stages 

















Figure 3.3. Expression levels of Schistosoma haematobium tetraspanin mRNAs at different 
life stages. Relative mRNA expression levels of (A) Sh-tsp-2, (B) ms3_01370, (C) ms3_09198, 
(D) ms3_05289, (E) ms3_01153 and (F) ms3_05226 were analysed by qPCR and normalised 
to a housekeeping gene (a-tubulin) using the 2−ΔΔCt method using the egg stage as a reference 




3.3.5. Schistosoma haematobium tetraspanins are expressed in the tegument and internal 
organs of S. haematobium adult worms 
To determine the location of Sh-TSPs in the adult worms, sections from S. haematobium 
adult worms were probed with mouse polyclonal antibodies produced against each of the 
selected Sh-TSPs (Fig. 3.4A-F). MS3_01153 (Fig. 3.4A) and MS3_09198 (Fig. 3.4C) were 
identified both on the tegument and gut of the worms, whereas Sh-TSP-2 (Fig. 3.4B) and 
MS3_05289 (Fig. 3.4D) were identified only on the tegument of the worms. MS3_01370 
(Fig. 3.4E) had a diffused expression whereas MS3_05226 (Fig. 3.4F) was identified both 
on the tegument and gastrodermis of adult worms. S. haematobium adult worm sections were 















Figure 3.4. Localisation of Schistosoma haematobium tetraspanins in adult worms. 
Immunolocalisations of Sh-TSPs in adult worm sections (A) MS3_01153, (B) Sh-TSP-2, 
(C) MS3_09198, (D) MS3_05289, (E) MS3_01370, (F) MS3_05226 and (G) TrX. Sections 
were probed with anti- Sh-TSPs followed by goat-anti-mouse IgG-Alexa Fluor. Fluo: 































TSPs are a family of proteins that consist of four transmembrane domains, an SEL and an LEL. 
TSPs are involved in numerous activities of cells [156] and they can also be involved in host-
parasite interactions. Indeed, some of them are being tested as potential vaccine candidates 
against diverse trematodes [161, 163, 268]. The first TSP identified in S. mansoni was Sm23 
[149] and, since then, other TSPs have been found in the proteome of schistosomes [14, 16, 
17, 21]. Sm23 is one of the independently tested WHO vaccine candidates [293] and its S. 
japonicum ortholog (Sj23) has also been found to be an efficacious vaccine in animal models 
of schistosomiasis [163, 164]. Recently, the S. haematobium ortholog of Sm23 (MS3_09198), 
and 5 other additional TSPs were identified in the proteomic analysis of the EVs from S. 
haematobium adult worms and, in this chapter, we aimed to characterise them to increase our 
knowledge of this important family of proteins. 
Sh-TSP-2, MS3-09198, MS3_02232 and MS3_01370 are grouped together in the CD63 
clade of TSPs, together with known S. mansoni, S. japonicum and O. viverrini vaccine 
candidates [160, 161, 163, 293], suggesting the usefulness of these S. haematobium EV TSPs 
as vaccine candidates against urogenital schistosomiasis. On the other hand, MS3_05289, 
MS3_05226, MS3_01153, MS3_07569, MS3_08458, MS3_01905, MS3-03452, 
MS3_03944, MS3_01557, MS3_03883 and MS3_01094 are clustered under the uroplakin 
family of TSPs. MS3_09789 and MS3_09698 clustered under the CD9/81 family of TSPs. 
All Sh-TSPs formed a single clade distinct from vertebrate TSPs.  
All Sh-TSPs were expressed throughout all the assessed life stages of the parasite, albeit 
with differing expression patterns, as has been reported for S. japonicum [286] and S. 
mansoni [294]. Taken together with their detected presence in tegumental and ES proteomic 
studies [22] and in EVs, this data suggests that all Sh-TSPs are, upon infection, continuously 
exposed to the immune system. The highest levels of expression for ms3_01370, ms3_05226 
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and ms3_05289 were observed in miracidia, which implies that these Sh-tsps may have 
specific roles like hatching or host-finding in the intermediate snail. For ms3_1153, 
ms3_09198 and Sh-tsp-2, the highest levels of expression were observed in cercariae, 
cercariae and 24 h schistosomula, respectively. Similarly, the highest expression level of Sm-
tsp-2 was detected in egg [158]. On the contrary the highest expression level of Sj-tsp-2 and 
Sj23 were observed in adult male worms [268, 295]. Furthermore the highest expression level 
of CD63 tsps (Ov-tsp-2 and Ov-tsp-3) was observed in the egg stage [159]. This suggested that 
TSPs likely have different functions in different species of schistosomes.  
MS3_05226 is located on the tegumental syncytium as well as on the internal organs while 
MS3_01370 has a diffuse expression. Similarly, some S. japonicum TSPs (AAW27174.1 
and AAW26928) are also located on the tegument and internal organs of adult worms 
whereas others (AAW24863 and AAW26928) are located only in the internal organs of adult 
S. japonicum worms [286]. In contrast, Sh-TSP-2 and MS3_05289 are located exclusively 
on the tegument of adult S. haematobium worms and other TSPs from S. mansoni, O. 
viverrini and S. japonicum [17, 157, 159, 161, 286] also display this localisation pattern. 
These tegumental proteins might play an important role in tegument formation, maturation 
and stability [157-159]. Since the tegument is the most susceptible structure to host-mediated 
immune attack [296], the LEL regions of TSPs in schistosomes have been tested as vaccine 
candidates [161], and Sm-TSP-2 from S. mansoni has already completed phase I clinical trials 
[162]. MS3_09198 and MS3_01153 are identified on the tegument and gut of adult worms. 
Similarly, Sj-TSP-2 was also located on the tegument and gut of the adult worm [268]. The 
presence of these EVs TSPs in the gut of adult worms might indicate the involvement of 
these EVs TSPs in nutrient acquisition process.  
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The presence of Sh-TSPs in the tegument and gut of adult worm suggests the presence of, 
at least, two distinct populations of EVs, one originating from the tegument and another 
from the gut as occurs in F. hepatica [118]. 
S. haematobium EVs TSPs were expressed throughout all life stages. Some of the TSPs 
clustered with known other helminths vaccine and diagnostic candidates and these TSPs 
were identified on the tegument of the worms, and/ internal tissues of adult worms. This 
suggests the potential usefulness of characterising these TSPs from S. haematobium towards 




Chapter 4: Assessment of the vaccine efficacy of Schistosoma 
haematobium tetraspanins  
4.1. Introduction 
The current control program against schistosomiasis is aimed at reducing the morbidity caused 
by the parasite by regularly treating infected populations with praziquantel [297]. Despite the 
efforts made to control this devastating disease, schistosomiasis is still spreading to new 
geographical areas [298]. Furthermore, praziquantel treatment does not prevent reinfection [85] 
and is not effective against the immature stages of the parasite [299]. Hence, a vaccine that 
reduces disease severity and/or reduces transmission is needed to control and eliminate 
schistosomiasis [85]. Despite efforts over decades, there is no licensed and effective vaccine 
to control the transmission of S. haematobium infection [300]. The only vaccine candidate to 
have progressed into clinical trial is Sh28GST, however, a phase 3 trial conducted from 2009 
to 2012 in S. haematobium infected children did not report any significant efficacy due to the 
vaccine [91]. Therefore, it is important to continue identifying new target antigens in the effort 
to develop a vaccine against S. haematobium [300]. 
Proteins found on the tegument and ES products of schistosomes are integral to the survival of 
the parasites in the host [301]. The tegument of schistosomes plays an important role in 
protecting the worm from the host immune response [302] and it also helps the parasite to 
absorb nutrients and molecules [303]. Therefore, the tegument is crucial for infection, 
development and worm survival in the host and tegumental antigens could be useful vaccine 
targets [296]. Indeed, characterisation of the tegument and ES proteomes of adult S. 
haematobium has revealed many proteins of vaccine potential [22]. Helminth EVs are potential 
vaccine candidates and vaccination of mice with helminths EVs stimulates the production of 
the protective immune response that significantly reduces fecal egg counts; worm burdens, 
symptom severity and mortality induced by infection in subsequent parasite challenges [31, 
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210, 211]. Moreover, EVs from helminths also contain vaccine candidate antigens including 
TSPs [146]. The TSPs Sm23, Sm-TSP-1 and Sm-TSP-2, all found in the proteomic analysis of 
S. mansoni EVs [24], have been shown to be efficacious vaccines candidates against 
schistosomiasis [161, 284] and Sm-TSP-2 has completed phase I clinical trials [162]. In another 
study, vaccination of mice with Sj-TSP-2e reduced liver egg burden in the first trial but in trial 
2 and 3 this vaccine candidate had no effect in liver egg burden [268]. Similarly, Sj-TSP-2c 
had no effect in liver egg burden [283]. Immunisation of mice with Sj-TSP-2d decreased the 
liver egg and fecal egg burdens significantly [304]. Although the vaccine efficacy of TSPs in 
other schistosomes was well studied, no studies have been conducted on the vaccine efficacy 
of Sh-TSPs. Accordingly, the present study aimed to assess the vaccine efficacy of Sh-TSPs as 
a vaccine target against S. haematobium infection. Herein, I have selected three of the soluble 
Sh-TSPs characterised in chapter 3 (MS3_09198, MS3_01370 and Sh-TSP-2) and clustered 
together with known schistosome vaccine candidates [161, 268]. The vaccine efficacy of 
these Sh-TSPs were assessed in both a homologous (hamster; S. haematobium) and 
heterologous (mouse; S. mansoni) challenge model of schistosomiasis.
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4.2. Materials and Methods 
4.2.1. Parasite materials and experimental animals  
S. haematobium-infected B. truncatus and S. mansoni-infected Biomphalaria glabrata snails 
were provided by BRI (Maryland, USA). 
Male Syrian hamsters (Mesocricetus aureus) were used for the homologous challenge model 
as hamsters are a more permissive model for S. haematobium infection and literature supports 
the use of these animals [305]. Hamster vaccine trials were undertaken at BRI since hamsters 
are prohibited in Australia. Experiments were approved by the BRI Institutional Animal Care 
and Use Committee (protocol #18-01) and recognised by the Office of Laboratory Animal 
Welfare (assurance #A3080-01). Male Balb/c mice were used for the heterologous challenge 
model and vaccine experiments (approved under James Cook University Animal Ethics 
number A2391) were performed at James Cook University. 
4.2.2. Vaccine formulation and immunization schedule 
For the hamster vaccine trials, four groups of 8 male Syrian hamsters (6-8 weeks) were 
immunized intraperitoneally on day 1 with either recombinant Sh-TSP-2, MS3_09198, 
MS3_01370 or TrX control protein (50 μg/hamster), each formulated with an equal volume 
of Imject alum adjuvant (Thermofisher) and 5 μg of CpG ODN1826 (InvivoGen). 
Immunizations were repeated on day 15 and 29 and each hamster was challenged (abdominal 
penetration) with 200 S. haematobiumi cercariae on day 43. Blood was sampled at day 42 and 
126 (12 weeks post-infection) to determine pre- and post-challenge antibody titers. 
For the mouse vaccine trials, groups of 10 animals were immunised in the same way as 
hamsters and mice were challenged (tail penetration) with 120 S. mansoni cercariae on day 43. 




4.2.3. Necropsy and estimation of parasite burden 
Hamsters were necropsied at day 154 (16 weeks post-infection), mice were necropsied at day 
91 (7 weeks post-infection) and worms from both hosts harvested by vascular perfusion and 
counted. Livers were removed, weighed and digested for 5 h with 5% KOH at 37°C with 
shaking. Schistosome eggs from digested livers were concentrated by centrifugation at 1,000 
´g for 10 min and re-suspended in 1 ml of 10% formalin. The number of eggs in a 5 μl 
aliquot was counted in triplicate and the number of eggs per gram (EPG) of t h e  liver was 
calculated. Small intestines were removed and cleaned of debris before being weighed and 
digested as per the livers. Eggs were also similarly concentrated and counted to calculate 
intestinal EPG. 
4.2.4. Serum antibody response to vaccination in hamsters and mice 
An ELISA was performed to assess antibody titers to proteins (MS3_09198, MS3_01370 and 
Sh-TSP-2) using the serum collected at different time points during the experiment. Microtiter 
plate wells (Greiner Bio-One, Austria) were coated with 100 µl (2 μg/ml) of each protein in 
0.1 M carbonate-bicarbonate buffer (pH 9.6) and incubated overnight at 4°C. Plates were 
washed 3 times with phosphate buffer saline/0.05% Tween-20 (PBST) and blocked with skim 
milk powder (5% in PBST) at 37°C for 1 h. Then, plates were washed 3 times with PBST and 
100 µl of serially diluted mouse or hamster serum (1:5,000-1:1,280,000 in PBST) was added 
and incubated at 4°C overnight. After washing with PBST 3 times, 100 µl of HRP-conjugated 
anti-hamster or anti-mouse IgG (diluted 1:3,000 in PBST) (Sigma-Aldrich, USA) was added, 
incubated at 37°C for 1 h and washed 3 times with PBST. Finally, 100 μl of 3,3',5,5-
tetramethylbenzidine (TMB, Thermo Fisher Scientific, USA) was added and incubated for 12 
min at RT in the dark. The reaction was stopped with 3 M HCl and absorbance was measured 
at 450 nm using a POLARstar Omega (BMG Labtech, Australia).  
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4.2.5. Statistics  
All statistics were performed using GraphPad Prism 7.0. The worm number reduction and egg 
number reduction were analysed using a Student’s t test and results were expressed as the mean 
± standard error of the mean. For the hamster and mouse antibody titer, the reactivity cut-off 




4.3.1. Antibody response of hamsters and mice following immunisation and parasite 
challenge  
Hamsters immunised with all S. haematobium proteins produced specific IgG responses (Table 
4.1). Pre-challenge IgG endpoint titers were > 1,280,000 for all hamsters vaccinated with 
MS3_01370. Pre-challenge IgG endpoint titers for hamsters vaccinated with MS3_09198 
ranged from 160,000-1,280,000 except hamster 4, which had no detectable IgG response 
against the protein. For Sh-TSP-2, all hamsters had pre-challenge IgG endpoint titers > 
1,280,000, except hamster 8 (320,000). At 12 weeks post challenge, IgG titers ranged from 
10,000-640,000 for hamsters immunised with MS3_01370 while the IgG titers for MS3_09198 
ranged from 5,000-80,000. For Sh-TSP-2, the IgG titers 12 weeks post challenge ranged from 
10,000-320,000. Only 1 and 2 hamsters immunised with Sh-TSP-2 and MS3_01370, 
respectively, had antibody titers above 100,000 at 12 weeks post challenge. 
Mice vaccinated with all Sh-TSPs produced specific IgG responses (Table 4.2). Pre-challenge 
IgG endpoint titers were > 640,000 for all mice immunised with MS3_01370 in both trials. For 
Sh-TSP-2, all mice had pre-challenge IgG endpoint titers were > 640,000, except hamster 2 in 
trial 1 (160,000).  Pre-challenge IgG endpoint titers for mice vaccinated with MS3_09198 
ranged from 40,000-320,000 in both trials.  
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Table 4.1. Pre-challenge and pre-necropsy serum antibody response of hamsters immunised with Schistosoma haematobium tetraspanins 
Hamster IgG titers 
MS3_01370 MS3_09198 Sh-TSP-2 
Pre-challenge 12wk post challenge Pre-challenge 12wk post 
challenge 
Pre-challenge 12wk post 
challenge 
1 >1,280,000 80,000 >1,280,000 10,000 >1,280,000 20,000 
2 >1,280,000 40,000 >1,280,000 80,000 >1,280,000 10,000 
3 >1,280,000 10,000 >1,280,000 80,000 >1,280,000 80,000 
4 >1,280,000 160,000 Not detected Not detected >1,280.000 80,000 
5 >1,280,000 640,000 >1,280,000 20,000 >1,280.000 10,000 
6 >1,280,000 40,000 >1,280,000 5,000 >1,280.000 320,000 
7 >1,280,000 40,000 >1,280,000 20,000 >1,280,000 20,000 





Table 4.2. Pre-challenge serum antibody response of mice immunised with Schistosoma 
haematobium tetraspanins. 
Mouse Pre-challenge IgG titers 
MS3_01370 MS3_09198 Sh-TSP-2 
Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 
1 >640,000 >640,000 80,000 80,000 >640,000 >640,000 
2 >640,000 >640,000 40,000 160,000 160,000 >640,000 
3 >640,000 >640,000 80,000 160,000 >640,000 >640,000 
4 >640,000 >640,000 160,000 160,000 >640,000 >640,000 
5 >640,000 >640,000 160,000 80,000 >640,000 >640,000 
6 >640,000 >640,000 160,000 40,000 >640,000 >640,000 
7 >640,000 >640,000 40,000 320,000 >640,000 >640,000 
8 No sample >640,000 160,000 No sample >640,000 >640,000 
9 No sample No sample No sample No sample >640,000 >640,000 
 
4.3.2. Parasite burdens in vaccinated and control hamsters 
Vaccination of hamsters with MS3_01370 and Sh-TSP_2 decreased worm burden by 22.46% 
and 8%, respectively. However, these reductions were not statically significant (Fig 4.1A). 
There was no difference in adult worm burden between hamsters vaccinated with MS3_09198 
and the control group. Interestingly, immunisation of hamsters with MS3_01370 and Sh-TSP-
2 significantly reduced the liver egg burden by 77.8% (P<0.01) and 52.27% (P<0.05), 
respectively when compared with the control group (Fig 4.1B). There was no difference in 
liver egg burden between hamsters vaccinated with MS3_09198 and the control group (Fig 
4.1B). Similarly, there was no difference in intestinal egg burden between hamsters vaccinated 




Figure 4.1. Schistosoma haematobium worm and egg burden reduction of vaccinated and control 
hamsters. (A) Adult worm reduction, (B) liver egg reduction, (C) intestinal egg reduction. Differences 
between groups was analysed with a student’s t-test. * P < 0.05, ** P < 0.01.  
4.3.3. Parasite burdens in vaccinated and control mice 
Vaccination of mice with MS3_01370, MS3_09198 and Sh-TSP-2 reduced the adult S. 
mansoni worm burden in trial 1 (trial 2) by 22 (14)%, 12 (5)% and 2% (no reduction), 
respectively. All these reductions were not statically significant (except MS3_01370 in trial 1 
(P<0.05))  (Fig 4.2A,B). In trial 1, vaccination of mice with MS3_01370, MS3_09198 and Sh-
TSP-2 significantly reduced liver egg burden by 39% (P<0.05), 49% (P<0.001) and 32% 
(P<0.01), respectively (Fig 4.2C). In trial 2, MS3_01370, MS3_09198 and Sh-TSP-2 
significantly reduced the liver egg burden by 54% (P<0.001), 27% (P<0.05) and 49% 
(P<0.001), respectively (Fig 4.2D). Similarly, immunisation of mice with MS3_01370, 
MS3_09198 and Sh-TSP-2 reduced the intestinal egg burden by 57% (P<0.01), 51% (P<0.01) 
and 54% (P<0.001) in trial 1, respectively (Fig 4.2E). In trial 2, MS3_01370, MS3_09198 and 
Sh-TSP-2 reduced the intestinal egg burden by 36% (P<0.01), 39% (P<0.05) and 27% 




Figure 4.2. Schistosoma mansoni worm and egg burden reduction of vaccinated and control 
mice. (A) Adult worm reduction trial 1, (B) Adult worm reduction trial 2, (C) liver egg 
reduction trial 1, (D) liver egg reduction trial 2, (E) intestinal egg reduction trial 1, (F) intestinal 
egg reduction trial 2. Differences between groups was analysed with a student’s t-test. * 





In this chapter, the vaccine protective efficacies of the three Sh-TSPs was assessed in a hamster 
(S. haematobium) and mouse (S. mansoni) model of infection. 
The majority of the vaccinated hamsters and mice produced a strong antibody response against 
recombinant proteins and the antibody titers observed were in accordance with previous 
vaccine studies on other schistosome TSPs [161, 268, 287]. In these studies, the antibody titers 
before challenge showed no correlation with worm burdens or egg counts; similarly, pre-
challenge antibody titers of Sh-TSPs had no association with worm and egg burdens.  
Worm burdens of any group of vaccinated animals were not significantly reduced in either 
model, compared to controls, except MS3_01370 in mouse trial 1. Similarly, result was 
obtained in a vaccine efficacy assessessment of a native 28 kDa GST and keyhole limpet 
haemocyanin (KLH) vaccines from Schistosoma bovis [306]. In another study, vaccination of 
mice with one of the subclass of Sj-TSP-2 (Sj-TSP-2e) was performed in three independent 
trials [268]. In the first trial, vaccination of mice with Sj-TSP-2e resulted in a 36.4% (P<0.001) 
reduction in worm burden. However, in the second and third trial the adult worm burden 
reduction was not statistically significant [268]. Similarly, immunisation of mice with Sj-TSP-
2c subclass showed no protection, while immunisation with a mixture of seven recombinant 
Sj-TSP-2 subclasses resulted in a 16.92% (P=0.0044) reduction for the adult worm burden 
[283]. In another study immunisation of mice with Sj-TSP-2d resulted in the reduction of adult 
worm by 56% (P<0.0010) [304]. Sj-TSP-2 was found to be highly polymorphic and a total of 
9 different subclasses of Sj-TSP-2 cDNA sequences have been revealed, which might be 
responsible for the inconsistent efficacy of Sj-TSP-2 in vaccine studies [268, 283]. On the 
contrary, vaccination of mice with a S. mansoni orthologue (Sm-TSP-2) resulted in the  
reduction of the adult worm burden by 57% [161] and 25-27% [287] when administered with 
Freund’s and alum + CPG adjuvants, respectively. Sm-TSP-2 has completed phase I clinical 
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trials [162]. The low efficacy of Sh-TSPs might due to the polymorphic nature of Sh-TSPs. 
Vaccination of mice with a DNA plasmid construct encoding Sm23 reduced adult worm burden 
by 21-44% in three trials [284]. In another study, immunisation of mice with plasmid DNA 
constructs of Sm23 by microseeding and gene gun delivery methods resulted in 31-34% and 
18% protection, respectively [307]. Furthermore, immunisation of buffaloes with an 
orthologue of S. japonicum (Sj23) DNA reduced worm burden by 45.5% and the level of 
protection increased to 50.9% when the protein was fused with HSP-70 [308]. In another study, 
immunisation of buffaloes with the same DNA vaccine did not protect against S. japonicum 
challenge while it reduced worm burden in sheep by 41.7% [309]. The difference in the adult 
worm reduction  might be due to the high levels of polymorphism in DNA sequences of 
MS3_09198 within and between different Schistosoma species [310]. 
In humans infected with S. haematobium, eggs trapped in the urogenital organs stimulate the 
immune response that leads to the formation of granuloma and, ultimately, tissue fibrosis [48]. 
However, in an animal model, S. haematobium fails to establish a urogenital disease [58]; the 
adult worms are recovered from the portal vein and eggs are trapped in the liver and voided in 
the feces, similar to animal models of S. mansoni and S. japonicum infection [81]. Vaccination 
of hamsters with MS3_01370 and Sh-TSP-2 significantly reduced liver egg burden but not the 
intestinal egg burden and vaccination of mice with MS3_01370, MS3_09198 and Sh-TSP-2 
significantly reduced the S. mansoni liver and intestinal egg burden in both trials. These S. 
mansoni tissue egg reductions imply that these vaccine candidates could be effective in 
reducing egg-induced pathology and transmission of infection by decreasing the amount of 
eggs released into the environment. Similarly, vaccination of cattle with 28 kDa GST and KLH 
significantly reduced liver egg burden following S. bovis challenge [306]. Immunisation of 
mice with Sm-TSP-2 reduced the liver and intestinal egg burden by 64% and 65%, respectively 
[161]. In another study with different adjuvant Sm-TSP-2 reduced the liver egg burden by 20–
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27% in 2 independent trials [287]. Vaccination of mice with Sj-TSP-2e resulted in 26.5% 
reduction in liver eggs burden in the first trial but in trial 2 and 3 this vaccine candidate had no 
effect in liver egg burden [268]. Similarly, Sj-TSP-2c had no effect in liver egg burden but 
combination of Sj-TSP-2 reduced liver egg burden by 27.04% [283]. Immunisation of mice 
with Sj-TSP-2d decreased the liver egg and fecal egg burdens by 55% (52%), 58% (46%) when 
compared with TRX (PBS) controls, respectively [304]. Since eggs are the primary causes of 
pathology egg reduction in hamsters following immunisation with MS3_01370 and Sh-TSP-2 
might reduce the pathology. Similarly, immunisation of buffaloes and sheep with Sj23 had no 
effect in fecal and tissue egg burden [309]. These difference in the tissue egg burden reduction 
might be due to the female worm burden reduction by Sh-TSPs. 
The significant reduction in liver egg burden in both the heterologous and homologous model 
of infection described here indicates these vaccine candidates are effective against the adult 
stages of both S. mansoni and S. haematobium and they could potentially be incorporated into 
a pan-schistosome vaccine due to the geographical overlap between the two species [1].   
Vaccination of mice with MS3_09198, MS3_01370 and Sh-TSP-2 significantly reduced the 
liver and intestinal egg burden. In the case of homologous model of infection only MS3_01370 
and Sh-TSP-2 significantly reduced the liver egg burden but none of these vaccine candidates 
reduced the intestinal egg burden. 
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Chapter 5: Evaluation of Schistosoma haematobium tetraspanins 
as potential novel diagnostic markers  
5.1. Introduction 
Schistosomiasis is endemic in 54 countries, affecting a round 240 million people and 700 
million people are at risk. The World Health Organization designed strategy to control the 
morbidity by 2020 and to eliminate schistosomiasis by 2025 [311]. To achieve this goal, 
developing a sensitive, accessible and inexpensive diagnostic screening test is essential [312]. 
Urine microscopy has been widely used as a standard diagnostic technique for S. haematobium 
infections [68], as this technique is simple to perform, cheap and requires little specialised 
training [69]. However, the eggs are not frequently voided through urine, which underestimates 
the prevalence of S. haematobium in light infections [68, 69] and the sensitivity is low in HIV 
infected individuals [313].  
CCA and CAA are proteoglycan antigens of schistosomes, can be detected in serum and urine 
samples [314, 315] and can be used to assess infection intensity and therapeutic responses 
[316]. However, the accuracy of CCA in detecting S. haematobium infection is low in areas 
endemic to both S. mansoni and S. haematobium [76].  
Molecular detection of parasite-specific DNA, such as the tandem-repeat sequence Dra I, is a 
sensitive and specific technique for the diagnosis of schistosomiasis [79]. However, it is costly 
and difficult to apply in the field [83].  
Antibodies produced against different life stages of schistosomes can be detected in humans 
and used for the diagnosis of infection [69]. Despite the inability of antibody detection to 
distinguish between a current and recent (but cured) infection [11, 41, 73], detecting antibodies 
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formed against the diverse life stages of S. haematobium is a sensitive technique for the 
diagnosis of infections in areas of low infection intensity [71]. 
For better control and, eventually, elimination of schistosomiasis, both sensitive and specific 
diagnostic tests are needed. Recently, the proteomic composition of the egg and adult ES 
products as well as the tegument [22] from S. haematobium adult worms revealed many 
different proteins of diagnostic potential, including TSPs. TSPs from other helminths such as 
T. solium and S. japonicum have been suggested as potential diagnostic candidates [269, 270] 
and I hypothesize that Sh-TSPs might be similarly efficacious. Herein, I test the ability of Sh-
TSPs characterised in chapter 2 to diagnose S. haematobium infection from the urine of 
individuals from areas endemic for urogenital schistosomiasis. 
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5.2. Materials and methods 
5.2.1. Experimental animals 
Male BALB/c mice were purchased and maintained at the AITHM animal facilities on the 
Cairns campus of JCU as discussed previously (chapter 2.2.1). All experimental procedures 
performed on animals in this study were approved by the JCU animal ethics committee 
(ethics approval number A2391). 
5.2.2. Human urine samples 
A total of 96 urine samples from S. haematobium infected individuals from an endemic area 
of Zimbabwe were collected on three consecutive days for parasitological examinations. S. 
haematobium infection was assessed by microscopic examination of the parasite eggs from 
10 ml of filtered urine [317]. These urine samples were kindly provided by Prof Francisca 
Mutapi from University of Zimbabwe. Fourteen urine samples from Australian volunteer 
donors that had never travelled to schistosomiasis endemic areas were collected as a 
negative control. In line with WHO criteria, the infection level of urine samples collected from 
the endemic area were classified as either high (>50 eggs/10 ml of urine) (n=30), medium (11-
49 eggs/10ml of urine) (n=28), low (0.3-10 eggs/10 ml of urine) (n=32) and egg negative (0 
eggs/10 ml of urine) (n=17). To confirm the presence or absence of infection, egg negative 
urines were also tested for the presence of CAA using the UCAA2000 (wet format) as 
described previously [318]. Of these samples, 6 were positive for CAA and 11 were negative 
(which were discarded for further analyses). The collected urine samples were aliquoted and 
placed at -80°C until further use. The collection of urine from Zimbabwean individuals was 




5.2.3. Mouse serum samples 
Mice were infected with S. haematobium and S. mansoni cercariae as previously described 
(chapter 2.2.2). S. haematobium and S. mansoni infected mice were necropsied after 14 and 7 
weeks post infection, respectively and blood samples were collected. Blood samples from naive 
mice were collected as negative control. Sera was obtained by allowing the blood to clot 
followed by centrifugation at 10,000 ´g for 10 min and stored at -20°C. 
5.2.4. Enterokinase digestion 
The N-terminal thioredoxin from the cloned and expressed TSPs was cleaved using 
enterokinase following the supplier’s protocol. Briefly, after purification soluble TSPs were 
buffer exchanged with PBS followed by (20 mM Tris-HCl, 50 mM NaCl, 2 mM CaCl2, pH 8). 
Then, 2 mg/ml of TSPs were incubated with 2 µl of enterokinase (Biolabs, USA) at RT for 24 
h and re-purified as previously described (chapter 3.2.7). 
5.2.5. Indirect enzyme-linked immunosorbent assay 
An ELISA was performed to assess the diagnostic efficacy of the recombinantly expressed six 
Sh-TSPs using the serum of infected mice (pooled samples from four independent S. 
haematobium infections) and the urine from naturally infected Zimbabwean people. Microtiter 
plate wells (Greiner Bio-One, Austria) were coated with 50 µl (2 μg/ml) of protein, incubated, 
washed, blocked and washed again as discussed previously (chapter 4.2.4). Then, 50 µl of 
human urine (diluted 1:50 in PBST) or mouse serum (diluted 1:3,000 in PBST) was added, 
incubated and washed as described in chapter 4.2.4. Fifty µl of HRP-conjugated anti-human 
IgG or anti-mouse IgG (diluted 1:5,000 in PBST) was added, incubated at 37°C for 1 h and 
washed 3 times with PBST. Finally, 50 μl of TMB (Thermo Fisher Scientific, USA) was added 
and incubated for 12 min at RT, the reaction was stopped by 3 M HCl and the absorbance was 
measured as previously described (chapter 4.2.4).  
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5.2.6. Statistics  
All statistics were performed using GraphPad Prism 7.0. The urine diagnostic assay was 
analysed using a non-parametric Kruskal-Wallis test with multiple comparisons followed by 
Dunn’s post-test when comparing each infection intensity against the negative control at the 
same time. A non-parametric Mann Whitney test was used when the results from all infected 
individuals were combined and compared against results from the negative control. For both 
serum and urine ELISA, the reactivity cut-off points were determined as the average reactivity 
+ 3x standard deviations (SD) of the negative control. The diagnostic accuracy of Sh-TSPs was 
measured by calculating the area under the curve (AUC) of the Receiver Operating 
Characteristic (ROC) curve generated for each antigen and a frequency of recognition matrix 
(FoR). ROC curves were used to calculate sensitivity, specificity and the AUC. FoR was 
determined as a percentage by dividing numbers of OD450 values greater than the reactivity 




5.3.1. Schistosoma haematobium tetraspanins are recognised by the serum of infected 
mice 
As a first step towards the assessment of TSPs as diagnostic candidates, I performed an indirect 
ELISA to analyse the immunogenicity of these proteins in infected mice. Antibody levels 
against Sh-TSP-2, MS3_01370 and MS3_09198 were significantly higher in the serum of mice 
experimentally infected with S. haematobium compared to serum from uninfected mice, while 
MS3_05226 and MS3_01153 were only weakly recognised (Fig. 5.1A). TrX was used as a 
control and was not recognised by the serum of S. haematobium infected mice (Fig. 5.1A). 
To assess cross-reactivity with S. mansoni, an indirect ELISA was performed using the serum 
of mice experimentally infected with S. mansoni. Only MS3_09198, MS3_01370, MS3_05226 
and MS3_01153 were recognised by antibodies from S. mansoni infected mice (Fig. 5.1B). 
Figure 5.1. Recognition of Schistosoma haematobium recombinant tetraspanins by the serum 
of S. haematobium and Schistosoma mansoni infected mice. Bar graph showing the detection 
of S. haematobium tetraspanins using (A) S. haematobium infected and (B) S. mansoni infected 
mouse sera. The reactivity cut-off points were determined as the average reactivity + 3x 

















































5.3.2. Schistosoma haematobium tetraspanins are recognised by antibodies in the urine of 
naturally infected individuals from an endemic area 
The diagnostic efficacy of Sh-TSPs was further tested by their recognition of antibodies in 
urine from infected human subjects from an endemic area in Zimbabwe. Antibody levels to all 
Sh-TSPs were significantly higher in a pool of infected subjects compared to uninfected non-
endemic subjects (Appendix Fig. 2A-F). All Sh-TSPs were significantly recognised by high 
egg burden individuals compared to negative controls (urine samples from a non-endemic area) 
(Fig. 5.2A-F). Except for MS3_05289, all Sh-TSPs were significantly recognised by 
individuals with a medium egg burden compared to the negative control (Fig. 5.2A-F). Only 
MS3_01370, Sh-TSP-2 and MS3_09198 were significantly recognised by individuals with a 
low egg burden (Fig. 5.2A-C) and only MS3_01370, MS3_05226 and MS3_09198 were 
significantly recognised by egg-negative but CAA-positive individuals (Fig. 5.2B, C and E). 
Since the recombinant LEL domains of MS3_01370, MS3_09198, MS3_01153, 
MS3_05226 and MS3_05289 were expressed in E. coli as fusion proteins with TrX, the 
effects of TrX on the accuracy of the diagnosis of these TSPs was also confirmed by indirect 
ELISA. TrX was not recognised by high, medium and low egg burden individuals (Fig. 5.2G). 
To confirm further the effect of TrX, the N-terminal TrX from TSPs that were strongly 
recognised by antibodies from infected individuals (MS3_09198 and MS3_01370) was cleaved 
using enterokinase following the supplier protocol. An indirect ELISA was performed using 
digested MS3_09198 and MS3_01370. However, there was no significant difference between 
digested and non-digested TSPs (Appendix Fig. 3A-D). Similarly, enterokinase digested TSPs 
were significantly recognised when comparing the uninfected non-endemic group with 
infected individuals as a pool (Appendix Fig. 4A and B). 
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Figure 5.2. Urine IgG recognition of six Schistosoma haematobium tetraspanins from 
Zimbabwean infected individuals with different infection status. The antibody level was 
measured by indirect ELISA and indicated by OD values: (A) Sh-TSP-2, (B) MS3_01370, (C) 
MS3_09198, (D) MS3_05289, (E) MS3_01153, (F) MS3_05226 and (G) TrX. All the data was 
entered in GraphPad Prism 7 and analysed using a non-parametric Kruskal-Wallis test with 
multiple comparisons followed by Dunn’s post-test. * P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0002. Urine of non-infected individuals from a non-endemic area was used as 
negative control. The reactivity cut-off points were determined as the average reactivity + 3x 
standard deviation of non-endemic negative individuals (indicated by broken lines). 
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5.3.3. Predictive accuracy of Schistosoma haematobium tetraspanins for the diagnosis of 
S. haematobium infection  
The diagnostic accuracy of Sh-TSPs was measured by calculating the AUC of the ROC curve 
generated for each antigen (Fig. 5.3A-F) and a FoR matrix (Appendix Fig. 5 lane (A-H)). The 
ROC curves were used to calculate sensitivity, specificity and the AUC. FoR was used to 
calculate the percentage of OD450 values greater than the reactivity cut-off point. When 
comparing the uninfected non-endemic group with infected individuals as a pool, the highest 
accuracy of diagnosis was obtained with Sh-TSP-2 (0.98) followed by MS3_01370 (0.97), 
MS3_09198 (0.95), MS3_05226 (0.89), MS3_01153 (0.78) and MS3_05289 (0.70) (Fig. 5.3A-
F). The highest accuracy of diagnosis for individuals with high infection intensity was obtained 
with Sh-TSP-2 (1.0) and MS3-05226 (1.0) followed by MS3_09198 (0.98), MS3_01370 
(0.97), MS3_05289 (0.85) and MS3_01153 (0.78) (Fig. 5.3A-F). In the case of medium egg 
burden individuals, the highest accuracy of diagnosis was obtained with Sh-TSP-2 (0.99) 
followed by MS3_09198 (0.98), MS3_01370 (0.97), MS3_05226 (0.95), MS3_01153 (0.95) 
and MS3_05289 (0.72) (Fig. 5.3A-F). For individuals with low egg burden, the highest 
accuracy of detection was obtained with Sh-TSP-2 (0.99) followed by MS3_01370 (0.96), 
MS3_09198 (0.93), MS3_05226 (0.73), MS3_01153 (0.63) and MS3_05289 (0.51) (Fig. 5.3A-
F). In the case of egg negative but CAA positive individuals the highest accuracy of detection 
was obtained from MS3_01370 (0.97) followed by MS3_05289 (0.88), Sh-TSP-2 (0.86), 














Figure 5.3. Receiver operating characteristic (ROC) curves analysis of six Schistosoma haematobium 
tetraspanins. The diagnostic accuracy of S. haematobium tetraspanins to detect antibodies in the urine 
of infected individuals with differing infection status as well as using pooled urine from all individuals 
was measured by the area under the ROC curve. (A) Sh-TSP-2, (B) MS3_01370, (C) MS3_09198, (D) 
MS3_05289, (E) MS3_01153 and (F) MS3_05226. The urine from non-infected individuals from a 
non-endemic area was used as negative control. 
The FoR matrix was performed for each TSP (Appendix Fig. 5 lane (A-F)) and the highest 
values were obtained from Sh-TSP-2 (86.5%) (A) followed by MS3_01370 (83.5%) (B), 
MS3_09198 (80.4%) (C), MS3_05226 (79.2%) (F), MS3_01153 (44.8%) (E) and MS3_05289 
(39.6%) (D). For non-fused MS3_01370 and MS3_09198 the frequency of recognition matrix 
was 82.1% and 73.2%, respectively (Appendix Fig. 5 lane (G, H)). The sensitivity of Sh-TSP-
2, MS3_01370, MS3_09198, MS3_05226, MS3_01153 and MS3_05289 for the diagnosis of 
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S. haematobium infection was 86.5%, 83.5%, 80.4%, 79.2%, 44.8, and 39.6%, respectively 
while the specificity of all Sh-TSPs was 100%. 
5.3.4. Combining Schistosoma haematobium tetraspanins doesn’t affect sensitivity and 
predictive accuracy  
An indirect ELISA was performed using combinations of MS3_09198 and MS3_01370, as 
well as Sh-TSP-2 as described above by coating plates with equal amounts (50 ng/well) of each 
Sh-TSP, depending on the combination. All Sh-TSPs combinations (fused and non-fused) 
were also significantly recognised when comparing the uninfected non-endemic group with 
infected individuals as a pool (Appendix Fig. 6A-F). Sh-TSP-2 + MS3_01370, MS3_01370 + 
MS3_09198 and MS3_09198 + Sh-TSP-2 were significantly recognised by patients with a 
high, medium and low egg burden compared to negative controls (Fig. 5.4A, C and E). Sh-
TSP-2 + MS3_01370 and MS3_01370 + MS3_09198 were also significantly recognised by 
egg negative but CAA positive individuals (Fig. 5.4A and E). When comparing uninfected 
non-endemic group with infected individuals as a pool, the highest accuracy of diagnosis was 
obtained with Sh-TSP-2 + MS3_01370 (0.98) followed by Sh-TSP-2 + MS3_09198  (0.97), 
MS3_01370 + MS3_09198  (0.96) (Fig. 5.4B, D and F). The highest accuracy of diagnosis for 
individuals having high burden was obtained from the Sh-TSP-2 + MS3_01370 combination 
(1.0) and MS3_09198 + MS3_01370 (1.0) followed by Sh-TSP-2 + MS3_09198 (0.98) (Fig. 
5.4B, D and F). In the case of patients with a medium egg burden, the highest accuracy of 
diagnosis was obtained was obtained from TSP-2 + MS3_01370 combination (1.0) followed 
by MS3_09198 + MS3_01370 (0.98) and Sh-TSP-2 + MS3_09198  (0.95) (Fig. 5.4B, D and 
F). For individuals with a low egg burden, the highest accuracy was obtained from Sh-TSP-2 
+ MS3_09198 (0.99) followed by Sh-TSP-2 + MS3_01370 (0.98) and MS3_01370 + 
MS3_09198 (0.93)  (Fig. 5.4B, D and F), whereas for egg negative but CAA positive 
individuals, the highest diagnostic accuracy was obtained from Sh-TSP-2 + MS3_09198 (0.92) 
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followed by MS3_01370 + MS3_09198 (0.84) and by Sh-TSP-2 + MS3_01370 (0.76) (Fig. 
5.4B, D and F). Similarly, an indirect ELISA was performed using combinations of digested 
MS3_09198 and MS3_01370, as well as Sh-TSP-2 as described above and there is no 
difference between fused combinations (Appendix Fig. 7A-F). The frequency of recognition 
matrix was performed for the combinations of fused TSPs (Appendix Fig. 5 lane (I-K)) and the 
highest values were obtained for Sh-TSP-2 + MS3_01370 (86.6%) followed by MS3_01370 + 
MS3_09198 (84.2%), Sh-TSP-2 + MS3_09198 (77.2%). From combinations of non-fused 
TSPs the highest values were obtained for Sh-TSP-2 + MS3_01370 (87.6%) followed by 










































Figure 5.4. Urine IgG recognition and Receiver Operating Characteristic (ROC) curves analysis of the 
combination of three Schistosoma haematobium tetraspanins by Zimbabwean infected individuals with 
different infection status. The antibody levels were measured by indirect ELISA and indicated by OD 
values: (A) Sh-TSP-2 + MS3_01370, (C) TSP_2 + MS3_09198 and (E) MS3_01370 + MS3_09198. 
The diagnostic accuracy of the combination of the S. haematobium tetraspanins to detect antibodies in 
the urine of infected individuals with differing infection status as well as using pooled urine from all 
individuals was measured by the Area Under the Curve (AUC). (B) Sh-TSP-2 + MS3_01370, (D) Sh-
TSP-2 + MS3_09198 and (F) MS3_01370 + MS3_09198. All the data was entered in GraphPad Prism 
7 and analysed using a non-parametric Kruskal-Wallis test with multiple comparison followed by 
Dunn’s post-test. * P < 0.05 ** P < 0.01, **** P < 0.0002. The urine from non-infected individuals 
from a non-endemic area was used as negative control. The reactivity cut-off points were determined 






In most of the sub-Saharan African countries mass drug administration is the only 
option to control schistosomiasis [319]. However, praziquantel treatment is not helpful 
in reversing complications caused by schistosomiasis [69] and praziquantel acts only 
on adult stage worms [299]. For better control and elimination, an effective diagnostic 
tools that can detect cases from areas with different transmission dynamics and different 
prevalence intensities are required to provide meaningful assessments of the efficacy 
of intervention programs [69]. However, urine microscopy, the most common 
technique for the diagnosis of schistosomiasis, has low sensitivity in HIV infected 
individuals [313]. HIV-AIDS and schistosomiasis are highly prevalent in sub-Saharan 
Africa and co-infection is common [320]. Therefore, it is imperative that new 
diagnostic tools that address these hurdles and accelerate schistosomiasis elimination 
efforts are developed. In this study the diagnostic potential of antibodies against S. 
haematobium EV TSPs has been evaluated. 
The diagnostic accuracy of 6 Sh-TSPs was assessed using antibodies from mouse sera 
and human urine. As a result, Sh-TSP-2, MS3_01370 and MS3_09198 were 
significantly recognised by serum antibodies from experimentally infected mice. Sh-
TSP-2, MS3_01370 and MS3_09198 were found in the proteomic analysis of adult S. 
haematobium tegument, and a tegument extract of S. haematobium was strongly 
recognized by urine from S. haematobium infected human subjects [22]. Similarly, 
TSPs from other platyhelminths such as T. solium, O. viverrini, S. mansoni and S. 
japonicum are also recognised by antibodies of infected humans and experimental 
animals [149, 157, 159, 231, 269-271]. This, together with the localisation studies and 
gene expression patterns (chapter (3.3.4 and 3.3.5)), suggests that at least some S. 
haematobium TSPs are accessible to antibodies and are immunogenic during natural 
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infections. Interestingly, Sh-TSP-2 was not recognised by antibodies from S. mansoni 
infected mice, implying the potential usefulness of Sh-TSP-2 in the diagnosis of S. 
haematobium infections where both species are co-endemic. Motivated by these 
results, I decided to test the utility of these antigens for the diagnosis of S. 
haematobium infection by using them to detect antibodies in the urine of individuals 
infected with the parasite. Urine, not serum, was selected as the diagnostic fluid due 
to the relative ease of sample collection compared to serum, especially in field 
conditions [321]. In certain infectious disease states, the use of urine over serum for 
diagnosis because of the ease of collection may be at the expense of sensitivity, but I 
posit that, for S. haematobium infections, any potential decrease in detection limits may 
be mitigated by an increased level of IgG present in the urine, relative to that produced 
by kidney excretion, due to the serum antibody leakage into the bladder as a result of 
egg-induced damage to the epithelium [322]. Each Sh-TSP showed statistically 
significant recognition by all cohorts, including egg negative but CAA positive urine 
samples, highlighting the increased diagnostic sensitivity over egg microscopy. 
Further, the use of Sh-TSP combinations in diagnosis doesn’t affect the predictive 
accuracy of infection. The sensitivity of Sh-TSPs was less than crude protein mixtures. 
On the contrary the specificity of all Sh-TSPs was higher than crude protein mixtures 
[323]. With regards to diagnostic use, preparations of defined, recombinant antigens 
can offer an advantage over crude protein mixtures (such as soluble egg antigen and 
soluble worm antigen preparation) in that they represent a more standardised and 
sustainable resource for diagnosis. Indeed, the defined antigen preparations described 
herein have AUC and FoR values which exceed that of SEA [22], making them a 
potentially effective, as well as rigorous, tool for the non-invasive diagnosis of S. 




MS3_09198, MS3_01370 and Sh-TSP-2 are potential diagnostic candidates for the 
diagnosis of S. haematobium. Moreover, Sh-TSP-2 is an ideal diagnostic candidate to 





Chapter 6: General discussion and Future directions 
More than 100 million people are infected by S. haematobium [60]. The eggs released 
by adult female S. haematobium worms are associated with pathogenesis and infected 
individuals suffer from different urogenital abnormalities [35]. The genital ulcers 
caused by the infection results in sexual dysfunction and infertility in adults [324]. Most 
importantly, this parasite is responsible for the death of 150,000 people per year [35]. 
Efforts have been made to reduce the prevalence of schistosomiasis using praziquantel 
[298] but schistosomiasis is spreading to new areas [34] and is now the second most 
prevalent of the neglected tropical diseases [325]. 
The control strategy for schistosomiasis is shifting from targeting morbidity to 
elimination [326]. To eliminate the disease, effective drugs, a clean water supply, 
molluscicides to kill the intermediate snail hosts, sensitive diagnostic tools and a 
vaccine are indispensable [327]; however, the current diagnostic modalities of 
schistosomiasis have limitations (chapter 1.2.4) and there is no licensed and effective 
vaccine for this devastating disease. Moreover, praziquantel is the only drug available 
for schistosomiasis treatment, it doesn’t protect against re-infection and reports of 
resistance are emerging [328]. Therefore, there is an urgent need to develop both 
sensitive and specific diagnostic candidates, as well as vaccines, to eliminate urogenital 
schistosomiasis. 
Adult schistosomes use ES products and tegumental proteins to modulate the immune 
response and to escape host-mediated immune attack. [12, 13]. The ES and tegumental 
proteomes of different schistosomes have been characterised [14, 16-22, 329, 330] and 
have helped in the identification of molecules that play a key role in host-pathogen 
interactions. Since EVs are one of the components of ES products, the proteomic 
compositions of different helminths EVs have also been characterised [24, 25, 117-
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126], again revealing many proteins involved in host-parasite interactions. EVs and EV 
membrane proteins of helminths are also recognised by samples from infected animals 
[142, 159, 231], suggesting the potential usefulness of EVs for the diagnosis of 
helminth infection. In addition, immunisation of animals with helminth EVs have 
reduced parasite burdens and pathogenesis in subsequent parasite challenge [31, 160, 
210, 211]. Hence, I have characterised the proteomic composition of S. haematobium 
adult worm EVs to identify and evaluate EV-derived proteins, which could be effective 
as vaccine and diagnostic candidates. 
In chapter 2, S. haematobium EVs (sEVs and m/lEVs) were purified from adult worm 
ES products and their size and concentration were determined using an established 
procedure [24]. The most represented domains from sEVs were homologues of other 
helminth vaccine and drug targets such as proteasome subunits, TSPs, ferritin-like 
proteins and members of the cytosol aminopeptidase family [161, 185, 186, 255, 260, 
262]. Similarly, the most represented domains in S. haematobium m/lEVs were proteins 
involved in EV biogenesis and release: EF-hand, Ras family, TCP-1/cpn60 chaperonin 
family and TSP family proteins [97, 272, 278, 279]. In addition to these most abundant 
protein families, S. haematobium EV proteomics revealed homologues of other 
helminths vaccine candidates such as GST, saposin B domain-containing protein and 
calpain [91, 93, 94, 143, 191, 194-196].  
TSPs, markers of exosomes, are the second most abundant protein family in S. 
haematobium sEVs and fourth in m/lEVs. Similarly, TSPs are abundant members in 
different helminth EVs [24, 25, 117-123]. S. mansoni EV TSPs (Sm-TSP-2 and Sm23) 
have been found to be efficacious vaccine antigens [161]. Moreover, Sm23 was also 
found to be a potential diagnostic candidate [149, 231]. Therefore, six Sh-TSPs present 
in S. haematobium EVs were selected and further characterised with regards to their 
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vaccine and/or diagnostic potential. Based on their expression profile analysis (chapter 
3), six Sh-tsps were expressed throughout all the assessed life stages, albeit with 
differing expression levels. Similarly, tsps from S. japonicum [268, 286, 295], S. 
mansoni [294] and O. viverrini [159] were expressed throughout all the assessed life 
stages with differing expression levels. This result indicated that these Sh-tsps may 
have specific roles in the intermediate snail host and different life stages of the 
parasite.  
In chapter 3, the LEL regions from the Sh-TSPs were expressed in E. coli and 
antibodies to each protein were produced in mice to assess the sites of anatomical 
expression in adult worms. MS3_05226 was located on the tegument surface as well 
as on the internal organs while MS3_01370 has a diffused expression. Similarly, two 
S. japonicum TSPs were also located on the tegument and internal organs of adult 
worms while another two TSPs are located only in the internal organs of adult worms 
[286]. In contrast, Sh-TSP-2 and MS3_05289 are located exclusively on the 
tegument of adult S. haematobium worms, which is similar to TSPs from other 
schistosomes shown to be involved in tegument development [17, 157, 159, 161, 
286]. MS3_09198 and MS3_01153 are located on the tegument and gut of adult 
worms, which is similar to Sj-TSP-2 [268]. The presence of EV TSPs in the gut 
suggests the involvement of EVs in nutrient acquisition and the presence of these 
tegumental proteins in the EVs indicates that TSPs may facilitate changes in the cell 
membrane needed for the formation and release of EVs [331].  
The tegument is the most susceptible structure to host-mediated immune attack [296] 
and, as such, different tegumental TSPs from helminths have been effectively tested as 
vaccine candidates [160, 161, 163, 164, 268]. Herein, I selected three soluble Sh-TSPs 
(from those identified in chapter 2) that clustered together with known schistosome 
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vaccine candidates [161, 268] and assessed them for vaccine efficacy in both a 
homologous (hamster/S. haematobium challenge) and heterologous (mouse/S. 
mansoni challenge) model of schistosome infection (chapter 4). Immunisation of 
hamsters with MS3_01370 and Sh-TSP-2 significantly reduced the liver egg burden but 
not adult worm and intestinal egg burden following S. haematobium infection. 
Vaccination of mice with either of the three Sh-TSPs significantly reduced tissue egg 
burdens, suggesting the potential usefulness of developing these Sh-TSPs as anti-
pathology or transmission-blocking vaccines. 
The potential of Sh-TSPs to diagnose S. haematobium infection in individuals from 
an endemic population was examined in chapter 5 and this was motivated by 
localisation results (chapter 3) and a recent study documenting the diagnostic 
potential of molecules present in S. haematobium tegument and ES products [22], 
indicating that these molecules were accessible to the host immune system in a 
natural and active infection. As a proof of concept, Sh-TSPs were assessed for their 
recognition by sera from mice experimentally infected with S. mansoni or S. 
haematobium and three of the six Sh-TSPs (Sh-TSP-2, MS3_01370 and MS3_09198) 
achieved a positive result, an observation documented for other helminth TSPs, 
including the S. mansoni and S. japonicum orthologues of MS3_09198 [149, 157, 159, 
231, 269-271]. Interestingly, only Sh-TSP-2 was not recognised by antibodies from S. 
mansoni-infected mice, indicating the potential usefulness of Sh-TSP-2 in the 
diagnosis of S. haematobium infections in African and Middle East countries where 
both species are co-endemic [8]. The diagnostic efficacy of these TSPs was further 
assessed by testing urine samples from individuals naturally infected with S. 
haematobium for the presence of anti-Sh-TSP antibodies. All Sh-TSPs were 
significantly recognised by individuals with a high infection intensity and, except for 
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MS3_05289, all Sh-TSPs were significantly recognised by individuals with a medium 
infection intensity. Only MS3_01370, Sh-TSP-2 and MS3_09198 were significantly 
recognised by individuals with a low infection intensity and only MS3_01370, 
MS3_05226 and MS3_09198 were significantly recognised by egg-negative but CAA-
positive individuals. The recognition of these TSPs by egg negative but CAA positive 
urine samples indicates the higher sensitivity of Sh-TSPs over egg microscopy for 
the diagnosis of urogenital schistosomiasis. This might be due to the presence of IgG 
in urine of individuals infected with S. haematobium due to serum antibody leakage 
into the bladder as a result of bladder pathology caused by parasite eggs [322]. 
In this thesis, I have generated novel data on the proteomic composition of S. 
haematobium adult worm EVs and proteins found in the membrane of EVs (TSPs). 
This study provides a framework for characterisation of other proteins found in S. 
haematobium EVs which will undoubtedly play fundamental roles in host-parasite 
interactions. Furthermore, the compelling vaccine and diagnostic data generated herein 
provides a focus for intervention targets to help in the control and elimination of 
urogenital schistosomiasis. 
Future directions 
In chapter two of this thesis, the proteomic composition of S. haematobium EVs was 
determined. To allow for a better understanding of the role of S. haematobium EVs in 
host-parasite interactions, future studies will characterise the proteomic composition of 
different compartments as well as the nucleic acid composition of S. haematobium EVs.  
S. haematobium EVs were purified by ODG and the size distribution was determined 
by TRPS.  For further confirmation the size of S. haematobium EVs, future studies will 




In chapter 3 of this thesis, an immunohistochemistry analysis was performed to 
determine the anatomic sites of S. haematobium TSPs expression in adult worm 
sections using AxioImager M1 fluorescence microscope. To allow for a better 
understanding on the site of production and mechanism of release of EVs from the 
worms, future studies will perform immunogold labelling to see localisation of Sh-TSPs 
at the ultrastructural level. 
In chapter 4 of this thesis, Sh-TSPs showed significant vaccine potential, reducing 
tissue egg burden reduction in both homologues and heterologous models of infection. 
Additional research will aim at increasing the level of protection by performing vaccine 
experiments with the use of different adjuvants and a co-formulation of antigens.  
Sh-TSPs showed significant intestinal egg burden reduction in heterologous models of 
infection but not in homologues model of infection. Therefore, future studies will 
further explore the reasons for the non-reduction of intestinal eggs in homologues 
model of infection. 
Sh-TSPs significantly reduced the liver egg burden in both the heterologous and 
homologous model of infection. To see the effect of these egg reduction in the 
pathology, future studies will perform histological examination of liver tissue from 
these animals to see if the reduced egg count correlated to any difference in pathology. 
Furthermore, to understand the mode of action of the S. haematobium EVs-TSPs in 
reducing the egg counts will be further studied. 
In chapter 4 of this thesis, Sh-TSPs were recognised by antibodies from naturally 
infected human and experimentally infected mice. To determine whether the protective 
antibodies induced by the Sh-TSPs were actually targeting EVs or the tegument where 
they are also expressed, future studies will use antibodies from infected human/animal 
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to see if antibodies, from either infected humans or rodents, recognizing Sh-TSPs also 
label isolated S. haematobium EVs.  
I have assessed the diagnostic and vaccine potentials of EVs TSPs but due to scarcity 
of EVs materials I couldn’t assess the vaccine and diagnostic potentials of S. 
haematobium EVs. Therefore, future studies will assess the vaccine and diagnostic 
potentials of S. haematobium EVs. 
I have assessed the diagnostic potentials of Sh-TSPs by detecting antibodies from 
infected individuals. Future studies will assess the diagnostic potentials of these Sh-
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Table 1. List of oligonucleotide primers used for qPCR analysis of Schistosoma 
haematobium tetraspanins  
Proteins  Forward primer Reverse primer  
a-tubulin 5’GGGCGCGTCTAGATCATAAG3’ 5’GTCAACACCAACCTCCTCGT3’ 
MS3_01370 5’TGCTGTGCTGAGAGACGAAG3’ 5’GGACGGTTTGTCCAGATGAT3’ 
MS3_05226 5’AGCCCGAAATGGAAGTGATT3’ 5’TGGTTTCAAGCATCCATTATGT3’ 
MS3_09198 5’GGCCAAACATTCCAGCTTCA3’ 5’GCGACCCAAACAACAAGCTA3’ 
MS3_01153 5’TCCTGTACCGTGTTGCAAAA3’ 5’TGTGAATAGAACAACGAGCAACA3’ 
Sh-TSP-2 5’CACCACCGGAATCCTGTTTC3’  5’CATCATCACCGCGCTTTACA3’ 
MS3_05289 5’AAATTCCTCCAGCTTGCTGT3’ 5’TATGAACGGGAGGGCTGTTT3’ 
	 138	
 
Table 2. List of oligonucleotide primers flanking the large extracellular loop (LEL) region of Schistosoma haematobium tetraspanins.  
Tetraspanins Forward primers Reverse primers 
MS3_01370 Ncol-NdeI-F 5’CGCCCATGGGTCATATGAGAGACGAAGTAAAATCTCAG3’ XhoI-R-5’CGCCTCGAGCTTTTCAAAGAAGGAGATTAC3’ 
MS3_05289 Ncol-Ndel-F 5’CGCCCATGGGTCATATGGGCACACAAAGTTTGTGGAAG3’ XhoI-R-5’CGCCTCGAGTGGAATAGCTATGAACGGGAG3’ 
MS3_05226 Ncol-NdeI-F 5’CGCCCATGGGTCATATGAGAAAACAAGTCCCTCATACA3’ XhoI-R-5’CGCCTCGAGTTGATGTAATGGTTTCAAGCA3’ 
MS3_01153 Ncol-NdeI-F -5’CGCCCATGGGTCATATGTCTCGTAAAGATGAGATTGGC3’ XhoI-R-5’CGCCTCGAGATAATCCATATATTTAAGGAA3’ 
MS3_09198 Ncol-NdeI-F 5’CGCCCATGGGTCATATGGTAGCAGTTGTTTACAAAGAT3’ XhoI-R-5’CGCCTCGAGGTTGCGTTTCAAGAATGCTCC3’ 




Figure 1. The amino acid sequence alignment of Schistosoma haematobium tetraspanins large extracellular 
loop with their respective Schistosoma mansoni homologs. (A) Sh-TSP-2 and Sm-TSP-2, (B) MS3_01370 and 
Smp_173150, (C) MS3_09198 and AAA73525, (D) MS3_05289 and Smp_344440, (E) MS3_01153 and 
Smp_140000 and (F) MS3_05226 and Smp_041460. 
 
Sh-TSP-2     1 EKPKVKKHVTDALREFVKEYSHDEHVSKVLDEVQQKLQCCGADSSKDYVTPPPESCFKDG 
AAN17276     1 EKPKVKKHITSALKKLVDKYRNDEHVRKVFDEIQQKLHCCGADSPKDYGENPPTSCSKDG 
 
Sh-TSP-2    61 QIFKEGCVKKVSDLSKMH 
AAN17276    61 VQFTEGCIKKVSDLSKAH 
 
 
MS3_01370    1 RDEVKSQFLSLVKSSVNEYSKNPDFKNFLDKIQQEFQCCGSESSSDYTSSGQTVPDSCKD 
Smp_173150   1 REDVKTQFLSLVRSSVSEYSKNPDIKKFLDKLQQEFQCCGSESSNDYTSSGQTIPDSCKN 
 
MS3_01370   61 TKTKAIYSDGCSYKVISFFEK 
Smp_173150  61 PNTKVTYSDGCSNKVISFFEK 
 
 
MS3_09198    1 VAVVYKDRIDSEIDALMTGALDKPTPEITEFMDLIQSSFHCCGAKGPQDYGPNIPASCRG 
AAA73525     1 VAVVYKDRIDSEIDALMTGALDKPTKEITEFMNLIQSSFHCCGAKGPDDYRGNVPASCKE 
 
MS3_09198   61 ETTVYHEGCVPVFGAFLKRN 
AAA73525    61 ENLTYTEGCVSVFGAFLKRN 
 
 
MS3_05289    1 GTQSLWKEDYEKSITSRFVSKYRGTFGAFAISEFEDYSLKMDQLMIELECCGLQGSQDFS 
Smp_344440   1 GTQSLWKQDYEKSMTVRFESNYRGTFGAFSISEFDDYSLKMDKLMIELECCGLNGYQDFS 
 
MS3_05289   61 NTKSRWYQEGRKYSDGTTGDAIKIPPACCKYTSKDFWRKADYEKFQDNLKDKDCVKTTNE 
Smp_344440  61 NTRSSWYLVGRKYPDGTSGDEIKIPPACCKYTSKDFLRNADYGKFQDNLKNKDCVKTTNE 
 
MS3_05289  121 SNMNVGCLAAAKNKTAKTALPFIAIP 
Smp_344440 121 SNMNVGCLAAVNNKIQQRALPFISIP 
 
 
MS3_01153    1 SRKDEIGNKAVEMFETSVKNYQSMEANTLDSLVVGLISPPLQCCGVDGGSDFKSSPNFWK 
Smp_140000   1 SRKDEIGNRAIDLFETSVKNYQSMAANTIDSLVVGLISPPLQCCGVNNGDDFTTSPNFWR 
 
MS3_01153   61 NDTYGGKTYTNIEYPVPCCKMNQNYAISDSTCPDKFDDNNSNYKNGCRGPLKEFFLKYMD 
Smp_140000  61 NDTYGGKTYNNIAYPVVCCKLNQNYAIIDSTCPDQFNENNSNYKTGCRGPLKELFLKYMD 
 
 
MS3_05226    1 RKQVPHTFLIQFLNYSIHDYISISSGDPNSILMGLIMMKLNCCGARNGSDFYHPVKFNRT 
Smp_041460   1 SKQHPHKFLIQFLNYSFHEYVSISSGDPNSILMGLIMMKLNCCGARNGSDFYHPVKFNRT 
 
MS3_05226   61 DVWNGVTYTHLKYPLPCCQFKDNLEIQGDTCPNSFRNSNVHNGCLKPLHQ 















Figure 2. Urine IgG recognition of six Schistosoma haematobium tetraspanins from Zimbabwean 
infected individuals when comparing uninfected non-endemic group with infected individuals as a 
pool. The antibody level was measured by indirect ELISA and indicated by OD values: (A) Sh-TSP-2, 
(B) MS3_01370, (C) MS3_09198, (D) MS3_05289, (E) MS3_01153, (F) MS3_05226 and (G) TrX. 
All the data was entered in GraphPad Prism 7 and analysed using a non-parametric Mann Whitney test. 
* P < 0.05, *** P < 0.001, **** P < 0.0002. Urine of non-infected individuals from non-endemic area 
was used as negative control. The reactivity cut-off points were determined as the average reactivity + 
















Figure 3. Urine IgG recognition and ROC curves analysis of digested Schistosoma haematobium 
tetraspanins from Zimbabwean infected individuals with different infection status. The antibody level 
was measured by indirect ELISA and indicated by OD values: (A) MS3_01370, (C) MS3_09198. The 
diagnostic accuracy of enterokinase digested S. haematobium tetraspanins (TSPs) to detect antibodies 
in the urine of infected individuals with differing infection status was measured by the area under the 
ROC curve (AUC) (B) MS3_01370, (D) MS3_09198. All the data was entered in GraphPad Prism 7 
and analysed with a non-parametric Kruskal-Wallis test with multiple comparison by Dunn’s post-test. 
* P<0.05 ** P < 0.01, **** P < 0.0002. Urine of non-infected individuals from non-endemic area was 
used as negative control. The reactivity cut-off points were determined as the average reactivity + 3x 











Figure 4. Urine IgG recognition and ROC curves analysis of digested Schistosoma haematobium 
tetraspanins from Zimbabwean infected individuals when comparing uninfected non-endemic group 
with infected individuals as a pool. The antibody level was measured by indirect ELISA and indicated 
by OD values: (A) MS3_01370, (B) MS3_09198. All the data was entered in GraphPad Prism 7 and 
analysed with a non-parametric Mann Whitney test. **** P < 0.0002. Urine of non-infected individuals 
from non-endemic area was used as negative control. The reactivity cut-off points were determined as 

















Figure 5. Frequency of Recognition matrix (FoR) analysis of Schistosoma haematobium tetraspanins 
for the detection of Schistosoma haematobium infection. The diagnostic accuracy of S. haematobium 
TSPs to detect antibodies in the urine of infected individuals was measured by the Frequency of 
Recognition matrix (FoR) (lane A) Sh-TSP-2, (lane B) MS3_01370, (lane C) MS3_09198, (lane D) 
MS3_05289, (lane E) MS3_01153, (lane F) MS3_05226, (lane G) MS3_01370 (non-fused), (lane H) 
MS3_09198 (non-fused), (lane I) Sh-TSP-2 + MS3_01370 (fused), (lane J) Sh-TSP-2 + MS3_09198 
(fused), (lane K) MS3_09198 +MS3_01370 (both fused),  (lane L) Sh-TSP-2 + MS3_09198 (non-
fused), (lane M) Sh-TSP-2 + MS3_09198 (non-fused) and (lane N) MS3_09198 +MS3_01370 (both 
non-fused). Urine of non-infected individuals from non-endemic area was used as negative control and 
FoR was determined as a percentage by dividing numbers of OD450 values greater than the cut-off 

































Figure 6. Urine IgG recognition of combinations of fused and non-fused Schistosoma haematobium 
tetraspanins from Zimbabwean infected individuals when comparing uninfected non-endemic group 
with infected individuals as a pool. The antibody level was measured by indirect ELISA and indicated 
by OD values: (fused) (A) Sh-TSP-2 + MS3_01370, (fused) (B) Sh-TSP-2 + MS3_09198, (both fused) 
(C) MS3_09198 +MS3_01370, (non-fused) (D) Sh-TSP-2 + MS3_01370, (non-fused) (E) Sh-TSP-2 + 
MS3_09198 and (both non- fused) (F) MS3_09198 +MS3_01370. All the data was entered in 
GraphPad Prism 7 and analysed with a non-parametric Mann Whitney test. **** P < 0.0002. Urine of 
non-infected individuals from non-endemic area was used as negative control. The reactivity cut-off 
points were determined as the average reactivity + 3x standard deviation of non-endemic negative 


















Figure 7. Urine IgG recognition and ROC curves analysis of the combination of three non-fused 
Schistosoma haematobium tetraspanins from Zimbabwean infected individuals with different infection 
status. The antibody level was measured by indirect ELISA and indicated by OD values: (A) Sh-TSP-
2 + MS3_01370, (C) TSP_2 + MS3_09198, (E) MS3_01370 + MS3_09198. The diagnostic accuracy 
of combination of non-fused S. haematobium TSPs to detect antibodies in the urine of infected 
individuals with differing infection status was measured by the area under the ROC curve (AUC) (B) 
Sh-TSP-2  + MS3_01370, (D) Sh-TSP-2 + MS3_09198, (F) MS3_01370 + MS3_09198. All the data 
was entered in GraphPad Prism 7 and analysed with a non-parametric Kruskal-Wallis test with multiple 
comparison by Dunn’s post-test. ** P < 0.01, **** P < 0.0002. Urine of non-infected individuals from 
non-endemic area was used as negative control. The reactivity cut-off points were determined as the 
average reactivity + 3x standard deviation of non-endemic negative individuals (indicated by broken 
lines). 
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